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Mechanisms of BAK Activation in the Initiation of Mitochondrial Apoptosis
Abstract
Mitochondrial apoptosis is crucial for normal mammalian development and adult homeostasis being
regulated by B-Cell Lymphoma-2 (BCL-2) proteins. Deregulation of BCL-2 proteins form the basis for
myriad of human pathologies including cancer and autoimmune diseases. Therefore, BCL-2 proteins are
considered key therapeutic targets. BCL-2 homologous antagonist/killer (BAK) is an effector of outer
mitochondrial membrane (OMM) pemeabilization or mitochondrial poration. Despite progress in
understanding BAK-mediated mitochondrial poration, the underlying multi-step mechanism is not clearly
defined. Here, we provide mechanistic details on the early steps in this process related to BAK activation,
including transient direct activation and autoactivation. We demonstrate for the first time the
consequences of direct BAK activation by BH3 ligands for BAK destabilization, which is a requisite for
mitochondrial poration. Our high-resolution crystal structures of engineered BID BH3 ligands bound to
BAK have captured the rearrangements of a buried electrostatic network at the base of hydrophobic
groove, which explains the role of helix α1 destabilization in direct BAK activation. Furthermore, we
defined a novel mechanism of BAK autoactivation in trans whereby the exposed BH3 domain (helix α2)
engages dormant BAK in a “BH3-in-groove” conformation to amplify BAK activation in mitochondrial
poration. The crystal structure of the BAK BH3-BAK complex unveils the structural basis of in trans
autoactivation. The structure provides evidence for destabilization of the buried electrostatic network of
helix α1 similar to that observed during direct BAK activation. We comprehensively validated this
mechanism by mutagenesis in the context of BAK BH3 peptides and full-length BAK protein. Additionally,
we probed BAK activation with small molecules identified in a fragment-based screen as well by
modifying existing BCL-xL inhibitors. Our results suggest that alterations in helix α1 rearrangements are
common basis for both direct activation by BH3 ligands and helix α2 mediated autoactivation of BAK. It is
possible that both activation steps are required for formation of activated BAK intermediate which may
interact with outer mitochondrial membrane to form pores and subsequently initiate mitochondrial
apoptosis. Targeting both direct activation and autoactivation by mimicking the conformational changes
induced by BH3 peptides changes could serve as a potential strategy for treating number diseases
caused by deregulation of BCL-2 family proteins. Overall, our studies redefine BAK activation
mechanistically and provide strong preliminary data towards the design of small molecule BAK
modulators for apoptosis research.
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ABSTRACT
Mitochondrial apoptosis is crucial for normal mammalian development and adult
homeostasis being regulated by B-Cell Lymphoma-2 (BCL-2) proteins. Deregulation of
BCL-2 proteins form the basis for myriad of human pathologies including cancer and
autoimmune diseases. Therefore, BCL-2 proteins are considered key therapeutic targets.
BCL-2 homologous antagonist/killer (BAK) is an effector of outer mitochondrial
membrane (OMM) pemeabilization or mitochondrial poration. Despite progress in
understanding BAK-mediated mitochondrial poration, the underlying multi-step
mechanism is not clearly defined. Here, we provide mechanistic details on the early steps
in this process related to BAK activation, including transient direct activation and
autoactivation. We demonstrate for the first time the consequences of direct BAK
activation by BH3 ligands for BAK destabilization, which is a requisite for mitochondrial
poration. Our high-resolution crystal structures of engineered BID BH3 ligands bound to
BAK have captured the rearrangements of a buried electrostatic network at the base of
hydrophobic groove, which explains the role of helix α1 destabilization in direct BAK
activation. Furthermore, we defined a novel mechanism of BAK autoactivation in trans
whereby the exposed BH3 domain (helix α2) engages dormant BAK in a “BH3-ingroove” conformation to amplify BAK activation in mitochondrial poration. The crystal
structure of the BAK BH3-BAK complex unveils the structural basis of in trans
autoactivation. The structure provides evidence for destabilization of the buried
electrostatic network of helix α1 similar to that observed during direct BAK activation.
We comprehensively validated this mechanism by mutagenesis in the context of BAK
BH3 peptides and full-length BAK protein. Additionally, we probed BAK activation with
small molecules identified in a fragment-based screen as well by modifying existing
BCL-xL inhibitors. Our results suggest that alterations in helix α1 rearrangements are
common basis for both direct activation by BH3 ligands and helix α2 mediated
autoactivation of BAK. It is possible that both activation steps are required for formation
of activated BAK intermediate which may interact with outer mitochondrial membrane to
form pores and subsequently initiate mitochondrial apoptosis. Targeting both direct
activation and autoactivation by mimicking the conformational changes induced by BH3
peptides changes could serve as a potential strategy for treating number diseases caused
by deregulation of BCL-2 family proteins. Overall, our studies redefine BAK activation
mechanistically and provide strong preliminary data towards the design of small
molecule BAK modulators for apoptosis research.
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CHAPTER 1.

APOPTOSIS IN HEALTH AND DISEASE
Overview of Apoptosis

Cell death is a biological process in multicellular organisms, which regulates
development, tissue homeostasis, and removes redundant or harmful cells from the body.
Cell death is categorized into three groups based on the microscopic appearance of a cell:
apoptosis, autophagy and necrosis [1]. Apoptosis is the major mode of programmed cell
death first discovered in 1972 [2]. Cells undergoing apoptosis are characterized by
distinct morphological features including membrane blebbing, nuclear fragmentation, cell
shrinkage and chromatin condensation due to proteolytic activity of apoptotic caspases
[3-5]. Eventually, the cell contents are packed as “apoptotic bodies” enclosed by the
plasma membrane and engulfed by phagocytes. This process of phagocytic cell clearance
is efficient and leaves minimal damage or inflammation in the organism unlike necrosis,
which through swelling and rupture of plasma membrane releases inflammatory
constituents [3, 5]. Molecular insights into apoptosis research was revealed first time
through discovery of BCL-2 gene in follicular lymphomas. In this malignancy, BCL-2
gene translocation from chromosome 18 to 14 results in overexpression driven by its
fusion with the immunoglobulin heavy chain locus. The mystery of carcinogenesis by
upregulation of the prosurvival guardians, BCL-2 protein was resolved through the
understanding that BCL-2 does not enhance cell proliferation, rather blocks cell death [68].
Significance of Apoptosis in Human Physiology
Billions of cells die each day to maintain the equilibrium between cell
proliferation and cell death specifically in tissues with high turnover including intestinal
epithelium and hematopoietic system [3, 5, 9, 10]. This equilibrium regulates tissue
homeostasis and normal growth in human physiology. Furthermore, apoptosis provides
shape for limb formation during embryogenesis. Excess neurons are eliminated to
balance the high turnover of cells. Apoptosis mediates maturation of the red blood cells
and is also involved in the process of involution that eliminates the epithelial cells of milk
gland accumulated during pregnancy. It is also crucial for the normal functioning of
immune system; for example cytotoxic T cells and natural killer cells destroy virusinfected cells through apoptosis. Since apoptosis serves multiple roles for the normal
functioning of the body, its deregulation is implicated in several pathological conditions
such as cancer, auto-immune diseases, neurodegenerative disorders and hepatitis-C [3, 4,
10].
Apoptotic Signaling Pathways
In vertebrates, apoptosis is mediated through two signaling pathways which
eventually converges on the activation of caspases [9, 11]. These include the
1

mitochondrial or intrinsic pathway and the death receptor or extrinsic pathway. Caspases
are cysteine proteases with specificity for aspartic acid residues in their substrates [1],
which once activated cleave thousands of substrates to dismantle the cell from within. So
far there are 17 known caspases in mammals categorized into initiator or executioner
caspases. Initiator caspases (e.g. caspase-2, caspase-8 and caspase-9) exists in inactive
monomers and consist of prodomain (death effector domain [DED]), small subunit and
large subunit. Adaptor molecules like apoptotic protease-activating factor 1 (APAF-1)
when organized in caspase-activation platforms facilitates recruitment of initiator
caspases and brings monomer units into close proximity to convert them into active
dimers. Executioner caspases (e.g. caspase-3, caspase-6 and caspase-7) rely on initiator
caspases for their activation and consists of only small and large subunit. Proteolytic
cleavage between these subunits by initiator caspases convert them into activated dimers
and drives the destruction of multiple cell constituents. Specific cellular changes include
degradation of cytoskeletal and nuclear proteins, DNA fragmentation, formation of
apoptotic bodies and crosslinking of proteins. The most distinct alterations include
externalization of phosphatidylserine on plasma membrane of cell, which is recognized
and engulfed by macrophages for rapid clearance of cells [12].

Intrinsic or Mitochondrial Pathway
During mitochondrial pathway, intrinsic cellular stress such as DNA damage
induced by genotoxic agents or defects in DNA repair, endoplasmic reticulum (ER)
stress, growth factors deprivation, infections such as bacterial, viral and parasitic activate
BH3-only initiators [1, 13-15]. BH3-only initiators subsequently activate the effectors,
BAK and BAX (Figure 1-1A). The effector proteins then permeabilize the OMM
releasing proapoptogenic factors from the intermembrane space (IMS) into the cytosol.
These factors include cytochrome c (cyt c), second mitochondria-derived activator of
caspase (SMAC), and mitochondrially-located serine protease (OMI). Cyt c forms a 1:1
heptameric oligomeric complex with APAF-1 in the cytosol, known as the apoptosome,
which serves as an activation platform for the initiator caspase-9. The apoptosome
recruits caspase-9 and induces its activation through homodimerization. Active caspase-9
cleaves and activate executioner caspases-3 and 7. SMAC and OMI inhibit the action of
X-linked inhibitor of apoptosis protein (XIAP), which blocks the catalytic activity of
caspases-3 and 9. Caspases-3 and 7 execute cellular demise by dismantling thousands of
proteins and cell constituents [1, 3, 9, 11]. For example, caspase-mediated cleavage of
one subunit of complex I of the electron transport chain system deregulates ATP
production, mitochondrial potential and electron transport during apoptosis. Other
examples include caspase cleavage of DNAse, a caspase-activated nuclease, which
cleaves chromatin between nucleosomes. Other proteins become constitutively active
upon caspase cleavage for example gelsolin, p21-activated kinase 2 (PAK2) and Rhoassociated kinase I (ROCK1) which in turn cleaves cytoskeletal modulators during
apoptosis [1].

2

Figure 1-1.

Overview of intrinsic and extrinsic apoptosis.

A) Intrinsic apoptosis is triggered when cellular stress activates BH3-only initiators.
BH3-only initiators inhibit prosurvival guardians or directly activate effectors to promote
mitochondrial poration, which releases proapoptogenic factors like cyt c, SMAC and
OMI, to activate the caspase cascade downstream.
B) Extrinsic apoptosis is triggered through ligation of death receptors on plasma
membrane which recruits the adaptor protein, FADD. FADD directly activates caspase-8
which can directly cleave and activate executioner caspases-3 and 7, as well as cleave
BID to initiate the mitochondrial pathway.

3

Extrinsic or Death Receptor Pathway
The extrinsic pathway is triggered when extracellular ligands bind to death
receptors on cell membrane and induce their ligation through their intracellular death
domains. Examples of these receptors include FAS, Tumor Necrosis Factor Receptor
(TNFR) and TNF-related apoptosis-inducing ligand (TRAIL). Receptor ligation leads to
recruitment of another complex known as FAS-associated death domain protein (FADD)
(Figure 1-1B). FADD binds and activates initiator caspase-8 and forms death-inducing
signaling complex (DISC). Caspase-8 directly activates executioner caspases-3 or 7 or
cleaves BID generating active truncated BID (tBID), which is a potent BH3-only initiator
of the mitochondrial pathway [3, 11]. In cells such as hepatocytes, lower level of caspase8 is processed at the DISC and merges into mitochondrial pathway for amplification of
death signaling. This pathway is known as “Type II” extrinsic pathway. On the other
hand, in cells such as lymphocytes sufficient level of caspase-8 is processed at DISC and
do not require mitochondrial pathway for death signaling. This pathway is known as
“Type I” extrinsic pathway.
BCL-2 Family Proteins Regulate Mitochondrial Apoptosis
BCL-2 family proteins consist of at least 18 members. Their main role is to
regulate the integrity of the outer mitochondrial membrane through complex proteinprotein interactions among themselves, which sets the threshold for initiation of
mitochondrial apoptosis of any given cell [16, 17]. BCL-2 proteins are categorized on the
basis of their functions (Figure 1-2). The BH3-only initiators (BAD, BIM, BIK, BMF,
NOXA, and PUMA) contains only one domain and mediate downstream signal
transduction through BH3 helix-mediated protein-protein interactions. The prosurvival
guardians or antiapoptotic proteins (BCL-2, BCL-xL, MCL-1, BCL-w and A1) and the
effectors (BAK, BAX and BOK) consists of four BH regions [16, 17]. Prosurvival
guardians antagonizes the action of BH3-only initiators and effectors. The effectors
execute mitochondrial poration through an intricate multi-step mechanism involving
activation, elusive conformational changes, dimerization, and oligomerization that
eventually compromise the integrity of the outer mitochondrial membrane (OMM) [16,
17]. The majority of BCL-2 proteins contain a C-terminal transmembrane domain that
anchors them to the outer mitochondrial membrane [16, 17].
A controversy regarding effector activation mechanisms has occupied the
attention of the field for more than two decades. In earlier studies, it was believed that
BH3-only initiators trigger mitochondrial apoptosis strictly by antagonizing prosurvival
guardians thereby releasing effector proteins [18-20]. That model demanded that the
effectors are always kept in check by prosurvival guardians. Several studies have
suggested that the effectors require direct activation by BH3-only initiators, and indeed in
certain cell types (e.g. mouse embryonic fibroblasts) and tissues (e.g. liver) the effectors
are dormant [21-23]. It is now widely accepted that BH3-only initiators carry out their
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Figure 1-2.

Overview of BCL-2 family proteins.

BH3-only initiators contain BCL-2 homology 3 (BH3), which is common in all BCL-2
proteins. Prosurvival guardians and effectors share four BH domains that fold into a
globular domain made up of nine alpha helices. The transmembrane domain (TM)
anchors the BCL-2 proteins to the outer mitochondrial membrane.
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functions in two ways: through direct activation of BAK and BAX, and antagonism of
prosurvival guardians widely known as “unified model”. [21, 24, 25].
The interactions among BCL-2 proteins dictate mitochondrial poration. Several
assays including surface plasmon resonance (SPR), cyt c release assay, liposome
permeabilization assay and yeast two-hybrid analysis have been used to determine
specificities of BH3-only initiators for the BCL-2 effectors and guardians. CoImmunoprecipitation (Co-IP) and GST-pulldown assays also demonstrated that
individual BH3-only proteins have selectivity for prosurvival guardians. [18, 25-28]
Based on these studies, BID, BIM and PUMA are promiscuous and block the activity of
majority of prosurvival guardians. In contrast, BAD is specific for BCL-xL, BCL-2 and
BCL-w and NOXA is specific for MCL-1 and A1 (Figure 1-3A). The majority of
prosurvival guardians can block BAX activity but BAK is specifically inhibited by BCLxL, MCL-1 and BFL-1 (Figure 1-3B). BID, BIM and PUMA also activates BAX and
BAK (Figure 1-3C).
Structure homology among BCL-2 proteins revealed well folded globular
structure whereby hydrophobic central helix α5 is surrounded by seven amphipathic
helices. Helices α2, α3, α4 and α5 form the hydrophobic groove and interaction site for
BH3 domains of proapoptotic proteins. These interactions primarily take place on the
outer mitochondrial membrane where the majority of BCL-2 proteins are targeted
through the transmembrane domain [29].
Physiological Roles of BCL-2 Family Proteins
Transgenic and genetic deletion studies in mouse demonstrated the physiological
roles of BCL-2 proteins and associated pathological defects [3, 4, 10]. BCl-2 proteins
regulate the survival of all mammalian cells [3, 4]. BCL-xL and MCL-1 knockout mice
revealed defects in embryogenesis supporting their importance in normal development.
BCL-xL knock out mice did not survive after 14 days of embryogenesis and showed
severe neuronal development defects [4]. Additionally, BCL-xL deletion led to
thrombocytopenia, defective spermatogenesis, liver fibrosis and impaired maturation of
red blood cells [4, 30-32]. MCL-1 deleted mice had severe physiological defects and
embryos died even before implantation at blastocyst stage [33]. They also revealed the
essential function of MCL-1 in survival of progenitor cells, hematopoietic stem cells and
effector lymphocytes [34, 35]. Heart failure and cardiomyopathy defects were also seen
in MCL-1-/- mice [36]. BCL-2-/- mice did not survive until birth and had defects in the
immune system and renal epithelial cells which led to kidney diseases [37].
Since BID, BIM, and PUMA interact promiscuously with the prosurvival
guardians, their individual and combined deletion have shown major physiological
defects compared to BAD and NOXA. BIM deletion resulted in abnormal proliferation
and accumulation of myeloid and lymphoid cells which led to autoimmune diseases [38,
39]. Biochemical studies suggested that BIM drives apoptosis in response to growthfactor deprivation in various cell types including endothelial, epithelial, mast cells,
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Figure 1-3.

Complex interaction among BCL-2 family proteins.

A) BID, BIM and PUMA bind promiscuously to all prosurvival guardians, while BAD
and NOXA are more specific in their binding profile.
B) BAX is inhibited by all prosurvival guardians while BAK is inhibited by A1/BFL-1,
BCL-xL and MCL-1.
C) BID, BIM and PUMA activate BAK and BAX effector proteins.
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lymphocytes and neurons and thus BIM deletion impacts apoptosis in wide range of cells
[3]. Since BID is involved in death receptor pathway, loss of BID has shown resistance to
FAS ligand and resulted in lethal hepatitis [40]. The tumor suppressor protein p53
regulates transcription of PUMA and NOXA in response to DNA damage by radiation,
oxidative stress, and chemical agents [3, 4]. Therefore, PUMA and NOXA are critical for
DNA damage-induced apoptosis in different cell types including lymphocytes. Their
combined deletion led to lymphocyte resistance to apoptosis in response to gamma
radiation [41]. Deletion of BH3-only proteins like BAD, BIK, HRK and BMF have
shown mild defects in mice as they do not bind to prosurvival proteins promiscuously
like others.
BAX-/- mice revealed mild lymphoid hyperplasia, overgrowth of neurons and
defective sperm cell differentiation. BAK-/- mice had less severe defects compare to BAX/mice except mild overgrowth of platelets due to lack of cell turnover [42]. However,
BAX and BAK double knockout mice showed serious defects and majority of them died
during embryogenesis. They also developed webbed limbs and imperforate vaginas due
to abnormal development [43, 44].
Therapeutic Targeting of BCL-2 Family Proteins
Resistance to apoptosis and overexpression of prosurvival guardians has been
considered one of the hallmark of cancer [45]. Additionally, excess of apoptosis also
forms the basis for diseases like autoimmune diseases, neurodegeneration and ischemic
injury [4]. The understanding of protein-protein interactions among BCL-2 proteins has
rationally informed the drug discovery for inhibitors of prosurvival guardians [46].
However, progress towards targeting effectors is still in premature phase. Structural and
functional elucidation of prosurvival guardians in complex with BH3 peptides has laid
the foundation for the discovery of several small molecule inhibitors [29]. These
inhibitors mimic the activity of BH3 peptides and known as “BH3 mimetics” [46, 47].
These inhibitor small molecules target prosurvival guardians through binding to their P1P5 sub pockets of hydrophobic groove and subsequently releasing sequestered
proapoptotic protein from their groove. Wide range of BH3 mimetics small molecules
and peptidomimetics have been discovered, however their restricted selectivity for one
prosurvival guardians protein and off-targets toxicities halted their further progress [4648]. Additionally, other small molecules and have been proposed, which induce allosteric
modulation of the BCL-2 family proteins. Here we provide overview of some selective
prosurvival guardians and prapoptotic modulators.

BCL-2, BCL-xL and BCL-w Inhibitors
ABT-737 was discovered using NMR fragment-based screening and rational
structure-based drug design approach (SBDD). Co-crystal structure revealed that ABT737 engages P1-P4 hydrophobic sub pockets of all three members: BCL-2, BCL-xL and
BCL-w [49]. ABT-737 was further optimized to analog ABT-263 (Navitoclax), which
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entered into Phase I clinical trial [50]. Both ABT-737 and ABT-263 have shown sub
nanomolar affinity for all three prosurvival guardians. Navitoclax demonstrated
promising clinical efficacy in hematological and small cell lung cancer (SCLC)
malignancies. Both ABT-737 and ABT-263 exhibited side effects like platelets reduction
(thrombocytopenia) due to on-target effects on BCL-xL [51]. BM-1197, a dual inhibitor
of BCl-2 and BCL-xL, was designed based on aryl sulfonamide scaffold of ABT-737 and
ABT-263 which revealed subnanomolar affinity. It showed anti-tumor activity in several
xenograft models and reversible platelets reduction [52]. S44563, designed by Servier
revealed promising anti-tumor effects on patient-derived melanoma cell-lines and
xenograft models [53, 54]. AstraZeneca reported two dual inhibitors BCL-32 [55] and
AZD4320. AZD4320 showed preclinical activity in Acute Lymphocytic Leukemia (ALL)
xenograft model as well as other BCL-2 and BCL-xL driven cell lines. Drop in platelets
count was observed only after 72 hours [46].

BCL-2 Inhibitors
The structure of ABT-263 in complex with BCL-2 guided SBDD and
modifications of contacts with P4 sub pocket of BCL-2 led to first potent and BCL-2
selective BH3 mimetic, ABT-199 (Venetoclax) [56]. Venetoclax demonstrated
subnanomolar affinity (Ki = 0.01 nM) for BCL-2 and induced apoptosis in BCL-2dependent patient-derived cells lines as well as xenografts derived from leukemia and
lymphoma malignancies with minimal impact on platelet counts. Venetoclax was
approved by FDA in April 2016 for the treatment of chronic lymphocytic leukemia
(CLL) patients and its potency is currently being tested in multiple clinical trials as a
single agent [57]. Venetoclax has shown efficacy in combination with other
chemotherapies and immunotherapies such as rituximab, cyclophosphamide,
bendamustine and vincristine against xenograft models of non-Hodgkin Lymphoma,
multiple myeloma, acute myeloid leukemia (AML) and breast cancer. Vernalis and
Servier also generated a BCL-2 selective inhibitor, S55746, which entered Phase I
clinical trials as monotherapy for Non-Hodgkin lymphoma and CLL [58].

BCL-xL Inhibitors
The BCL-xL selective inhibitor, WEHI-539, was discovered through biochemical
AlphaScreen competition assay, which measured displacement of BIM BH3 from BCLxL but not MCL-1 [59]. Structural exploration of WEHI-539 in complex with BCL-xL
revealed stabilizing electrostatic contacts with P2 and P4 sub-pockets of BCL-xL. WEHI539 demonstrated nanomolar affinity for BCL-xL (IC50 = 1.1 nM) and 400-fold
selectivity over other prosurvival guardians. WEHI-539 induced apoptosis in BCL-xL
dependent cancer cell lines. However, due to its poor physicochemical properties and
absorption, distribution, metabolism, and excretion (ADME) profiling, it failed to show
any promising effects in animal tumor models. Abbvie optimized WEHI-539 using
SBDD and NMR-based fragment screening and generated better behaved BCL-xL
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selective inhibitors for cell-based (A-1155463) and in vivo studies (A-1331852) [60, 61].
A-1331852 bound to BCL-xL tightly in TR-FRET assay (Ki <0.010 nM) and is orally
bioavailable. It also showed 50-fold improvement in cellular activity and promising
efficacy in xenograft models of breast cancer, ovarian cancer and NSCLC. Recently,
proteolysis-targeting chimera (PROTAC) of ABT-263 was designed to degrade BCL-xL
through E3 ligase pathway in several BCL-xL dependent cancer cell lines and revealed
reduced toxicity towards platelets reduction. It also demonstrated excellent anti-tumor
properties in in-vivo and patient derived xenograft ALL models and also showed
promising synergistic effects with ABT-199 in several tumor models [62].(Figure 1-4).

MCL-1 Inhibitors
It has been challenging to target MCL-1 due to its rigid hydrophobic groove [63,
64]. Several small molecules have been reported as MCL-1 inhibitors but their progress is
hampered due to off-target activities or lack of cellular effects [46]. UMI-77 was
discovered through High Throughput Screening (HTS) and SBDD approaches and
possess moderate binding affinity (Ki = 490 nM) with MCL-1 [65]. UMI-77 revealed
antitumor effects in an in vivo pancreatic xenograft models. Other compounds were also
generated using fragment-based NMR screening approaches by growing 2-carboxy
indole core into P2 sub-pocket [66]. Compounds 4 and 5 from Fesik lab and A-1210477
from Abbvie have sub-nanomolar affinity for MCL-1 (Ki 0.045 nM and 0.05 nM,
respectively, what assays) and 1000-fold selectivity over BCL-xL and BCL-2. These
compounds induced apoptosis in MCL-1-dependent cancer cell lines of hematological
cancers however in vivo anti-tumor activity has not been reported yet. Servier and
Vernalis discovered S63845 through fragment-based NMR screening and SBDD, which
is the first potent and selective MCL-1 inhibitor with promising antitumor in vivo activity
[67, 68]. S63845 revealed subnanomolar affinity (Ki = 0.15 nM) and 1000-fold selectivity
over BCL-xL and BCL-2 with broad range of apoptotic activity in MCL-1 dependent
hematopoietic malignancies as well as effective therapy in an in vivo xenograft models of
lymphoma, AML and mutiple myeloma. It has also shown great efficacy in combination
therapy with ABT-199 against T-cell acute lymphoblastic leukemia cell lines [68]. Its
analog S64315/MIK665 are currently being evaluated in Phase I clinical trial for AML,
lymphoma and multiple myeloma [68]. It is also being tested in combination with
venetoclax in AML patients. AMG176 and AZD5991 are also identified as macrocyclic
MCL-1 inhibitors by Amgen and Astra Zeneca respectively [69, 70]. They both
demonstrated subnanomolar affinity with MCL-1. AMG176 has entered in Phase 1
clinical trial and induced apoptosis in MCL-1 dependent cell lines derived from
hematologic malignancies or multiple myeloma but has been put it on hold by FDA due
to cardiac toxicity. It also showed promising effects on xenograft models. AZD5991 also
revealed antitumor effects on multiple myeloma xenografts models.
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Figure 1-4.

BCL-xL specific inhibitors.

WEHI-539 was optimized to A-1331852 and A-115463 to improve its physicochemical
properties. DT2216, BCL-xL specific PROTAC is designed specificity by adding E3
ligase Von Hippel-Lindau (VHL) ligand and linker to the existing ABT-263.
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BAX and BAK Activators or Inhibitors
Directly targeting BAK and BAX to activate or inhibit mitochondrial apoptosis is
a desirable strategy for treating myriad of pathologies with BCL-2 protein deregulation.
Better understanding of BAX and BAK molecular mechanism in last decade has led to
some preliminary small molecules but none of them have progressed towards clinical
studies yet or their direct mode of binding with effector proteins is not clearly defined
[71].
One of the trigger sites in BAX was found on opposite side of hydrophobic
groove and consist of helices α1 and α6 and used as a targeting site [72]. BAM-7 and its
analog BTSA1 were discovered as BAX activators through virtual screening [73, 74]. In
competitive fluorescence polarization assays, these compounds displace BIM SAHB
from BAX with IC50 of 3 µM and 250 nM, respectively. They initiate BAX activation by
binding to α1-and-α6 trigger site. BTSA-1 induced 6A7 antibody epitope exposure, BAX
oligomerization, and mitochondrial membrane permeabilization. BTSA-1 is selective for
BAX over BAK in cell-based assays and induced cell death in AML cell lines both in
vitro and in vivo. However, due to lack of co-crystal structure, the mechanism of
interaction with BAX is not known. It is also not known if these compounds bind the
canonical hydrophobic groove of BAX to induce its activation. Compound 106 was also
identified through virtual screening and is predicted to bind the canonical hydrophobic
groove of BAX to induce its activation [75]. It is selective for BAX over BAK when
investigated in BAK and BAX double knockout mice embryonic fibroblasts (MEFs)
reconstituted with the respective effectors, and shows antitumor effects in vitro and in
vivo. OICR766A was discovered through liposome permeabilization assay-based
screening and induced activation of BAX in both liposome (EC50 ~100 nM) and
mitochondria (EC50 ~900 nM) based assays [76]. It also induced membrane localization,
oligomerization and induced activity through C126 residue. OICR766A activity was
disrupted in BAK and BAX knockout baby mouse kidney cells suggesting BAK and
BAX dependent apoptosis.
BAX inhibitors compounds (BAIs) impaired BID induced BAX-mediated
liposome permeabilization (IC50 ~ 4µM) and bound at the bottom of hydrophobic groove
(Kd ~15 µM). These compounds were BAX selective over BAK and predicted to block
conformational changes associated with its activation and oligomerization [77]. However,
their antitumor effects is not known in vitro and in vivo. Distant analogs of BAIs,
trifluoroperazine (TFP) has also shown to block BAK-dependent apoptosis and binds
weakly to BAK (Kd ∼70 µM) [78]. However, their direct mode of interaction is also not
known. Other BAK and BAX modulators include MSN-125 and its analogs, which
apparently disrupt α6 and α9 mediated chemical crosslinking and are predicted to inhibit
higher order oligomerization [79], but their direct mode of interaction is elusive.
Recently, rationally designed BIM peptides were shown to inhibit BAK activity in
liposome permeabilization and cyt c release assays [80]. The artificial amino acid with
pentyl carboxylate group was introduced at the hydrophobic amino acid position (3) of
BIM BH3 peptide to generate BIM H3Pc, which exhibits improved binding to BAK by
several fold compared with WT BID BH3 (KD ~1.3 µM) and remarkably inhibits BAK.
BIM H3Pc also binds BCL-xL and MCL-1 and further structure-guided modification with

12

carboxylate containing moiety at (3) enhanced the selectivity for BAK over the
prosurvival guardians. The modified peptide included a BID-like modification at position
(0) (BIM h0-h3 Glt) exhibiting subnanomolar affinity (Kd =14.9 nM) for BAK and
inactivating BAK in mitochondria and liposome permeabilization assays.
Antibodies (Ab) and non-BH3 peptides have been reported to induce allosteric
modulation of effectors. Ab 7D10 binds the α1-α2 loop region to induce BAK
conformational changes leading to BAK oligomerization and activation [81]. While these
reagents are useful biochemical tools to prove the mechanisms of BAK activation, the use
of Ab to activate BAK in cells and in vivo is nontrivial. Stapled peptides were designed
based on the BH4 domain of BCL-2 protein and bound to BAX with nanomolar affinity
to block its activation [82]. NMR analysis suggested that this peptide binds to residues on
α1, α1-α2 loop, and α2-α3 and α5-α6 hairpins and it is predicted to induce BAX
inhibition through allosteric modulation. A helical peptide from human cytomegalovirus
viral mitochondria-localized inhibitor of apoptosis (vMIA) was also identified to bind to
α3-α4 and α5-α6 hairpins of BAX and blocked its activation through allosteric
conformational modulation [83]. BIF-44 fragment was identified through NMR-based
screening and bound at the pocket formed at the junction of helices α3-α4 to induce BAX
activation. It induced its activation by allosterically regulating the α1-α2 loop and
activated synergistically in the presence of BIM SAHB peptide [84]. Selective
prosurvival guardians and effectors modulators are summarized in (Table 1-1).
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Table 1-1.

Selective BCL-2 family proteins modulators.

Compound
/Peptide
ABT-737
ABT-263
BM1197
S44563
BCL-32
AZD4320
ABT-199
S55746
WEHI-539
A1155463
A1331852
UMI-77
S63845/S63415
AMG176
AZD5991
BTSA1
Compound 106
OICR766A
BAIs
MSN-125
BIM H3Pc / BIM h0-h3 Glt
7D10
BCL-2 BH4 SAHB
vMIA
BIF-44

Protein Targets

In vivo Antitumor
Effects
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No

BCL-2, BCL-xL,BCL-w
BCL-2, BCL-xL,BCL-w
BCL-2, BCL-xL
BCL-2, BCL-xL
BCL-2, BCL-xL
BCL-2, BCL-xL
BCL-2
BCL-2
BCL-xL
BCL-xL
BCL-xL
MCL-1
MCl-1
MCL-1
MCL-1
BAX
BAX
BAK
BAX
BAK, BAX
BAK
BAK
BAX
BAX
BAK and BAX

Clinical Stage
Phase II

FDA-approved
Phase I

Phase I
Phase I
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[58]
[59]
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[67]
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[70]
[74]
[75]
[76]
[77]
[79]
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[84]

Sources: Garner, T.P., et al., Progress in targeting the BCL-2 family of proteins. Curr Opin Chem Biol, 2017. 39: p. 133-142.
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2017. 16(4): p. 273-284.
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CHAPTER 2.

MODELS OF BAK CONFORMATION TRANSITION DURING
MITOCHONDRIAL PORATION

BAK, BAX and BOK are effector proteins, which possess the ability to interact
directly with outer mitochondrial membrane to drive mitochondrial apoptosis [16, 71].
The crucial role of effector proteins in mitochondrial apoptosis has been supported by
genetic deletion studies in animal models as they develop abnormal phenotype or do not
survive due to defective mitochondrial apoptosis. [86]. Recent studies also revealed that
effector protein, BOK induced mitochondrial poration in the absence of BAK and BAX
and is not regulated by BCL-2 proteins [87, 88]. A multi-step mechanism of BAK and
BAX activation involving conformational transitions has been proposed, wherein BAK
and BAX are engaged by direct activators, which trigger key conformational changes that
promote BAK unfolding in the presence of membrane environment. Active BAK and
BAX are thought to dimerize and subsequently oligomerize into poorly-defined pore-like
structures that release cyt c and induce mitochondrial apoptosis. Despite significant
progress in the field, it remains elusive how BAK and BAX assemble to initiate
mitochondrial poration. It is necessary to understand fully activated intermediates of
BAK and BAX, which will further provide insights into their self-association to form the
apoptotic pore. Here, we discuss biochemical and structural evidence specifically for
BAK conformation transitions during mitochondrial poration, missing links of the
established models and our proposed model to understand BAK activation mechanism.
Evidence for Models of BAK Conformation Transition
BID BH3 Protein Directly Activates BAK Through Transient Binding or “Hit-andRun” Activation Mechanism
In healthy cells, BAK stays in dormant conformation until triggered by apoptotic
stimuli to undergo conformational activation. Crystal structure of transmembrane domain
truncated dormant BAK demonstrated globular fold whereby α5 hydrophobic helix is
surrounded by seven amphipathic helices similar to prosurvival guardians [89] (Figure
2-1A). Transmembrane domain or α9 helix constitutively localizes BAK on outer
mitochondrial membrane [90, 91]. In response to apoptotic stimuli, BH3-only proteins
are activated through cleavage, translocation, upregulation or phosphorylation to initiate
mitochondrial apoptosis [1, 3]. Activated BH3-only proteins for example BID, BIM and
PUMA then bind directly to the “α2 - α5” helices of BAK, which form a hydrophobic
groove [22]. The interaction of BH3-only proteins with BAK is a first step to trigger the
conformation transition of dormant BAK into activated intermediate conformation. BID
BH3 activator binds weakly to BAK (KD ~10 µM). Transient binding is critical for the
“hit-and-run” activation mechanism, whereby BID dissociates from the hydrophobic
groove to allow downstream conformational changes in effectors[22]. Due to weak
affinity, structural analysis using X-ray crystallography for BAK in complex with
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Figure 2-1.

Dormant BAK and BID SAHB bound BAK structure.

A) Crystal structure (PDB: 2IMT) of C-terminally truncated dormant BAK with α5 as a
central hydrophobic helix surrounded by seven amphipathic helices.
B) NMR solution structure (PDB: 2M5B) of BID SAHB (red) bound to BAK (gray).
Hydrophobic residues of BID accommodate deeply within hydrophobic groove of BAK.
Other BID residues establish salt bridge network with BAK which is a conserved
interaction in all BCL-2 members.
Sources: Moldoveanu, T., et al., The X-ray structure of a BAK homodimer reveals an
inhibitory zinc binding site. Mol Cell, 2006. 24(5): p. 677-688.
Moldoveanu, T., et al., BID-induced structural changes in BAK promote apoptosis. Nat
Struct Mol Biol, 2013. 20(5): p. 589-597.
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activators has been quite challenging. To improve the helicity and affinity, chemically
stapled BID BH3 stabilized alpha helix of BCL-2 protein (SAHB) in complex with Cterminal truncated BAK (cBAK) was studied using NMR solution structure, which
revealed specific molecular determinants for BAK direct activation. Residues D98 and
D95 of BID SAHB peptide established salt bridge interactions with N124 and R127 of
BAK respectively (Figure 2-1B). The salt bridge interaction between D95 and R127 is
conserved in all BH3 complexes of BCL-2 family members [3, 4]. In the apo dormant
BAK conformation, Y89 side chain is centrally located to block the hydrophobic groove
[89]. In activated BAK conformation, Y89 chain is displaced by BID SAHB peptide as it
accommodates I86, L90, V93 and Nle 97 deeply within the hydrophobic groove [22].
Furthermore, activation of BAK by BID SAHB was tested biochemically in cyt c release
and calpain-mediated limited proteolysis assays. Transient hit-and-run mechanism was
validated by substituting L183 and G184 residues of BAK and I101 of BID SAHB to
cysteines. These two cysteine residues (L183C and G184C) were juxtaposed to I101C
and tethered through disulfide bond formation. BID SAHB and BAK tethered complexes
are impaired in mitochondrial permeabilization assays suggesting that these complexes
are inhibitory and supporting indirectly the transient hit-and-run mechanism of direct
BAK activation. In other studies, domain-swapped dimers were produced in the presence
of nonionic detergent CHAPS and crystallized in complex with BID BH3 peptide [92].
This structure also suggested similar mode of binding of BID at the hydrophobic groove
of BAK. However, helices α2 - α5 (core) were separated from helices α6 - α8 (latch) and
interacted with partner BAK molecule. The BAK domain-swapped dimer formation
suggested BH3-induced core and latch separation as key transition in BAK conformation.
The structures of BID activator peptide bound to BAK have revealed six turn helical
peptides binding to hydrophobic groove through six or seven hydrophobic residues and
conserved arginine-aspartate salt bridge interaction. Additionally, direct BAK activation
has also been evaluated biochemically using full length protein in liposome model system
and cyt c release assay supporting hydrophobic groove binding by BH3 activators [93].
α1 Helix Dissociation Is an Early Step of BAK Conformation Transition
In early 1999, it was demonstrated that N-terminus of BAK is exposed during
apoptosis [94]. Human Jurkat and T-lymphoma cells were exposed to apoptotic stimuli,
which revealed several fold increase in BAK-associated immunofluorescence measured
using BAK Ab-1 monoclonal antibody. BAK Ab-1 antibody specifically recognizes
amino acid residues 38-45 of BAK. Recently, this observation was validated by Nterminal epitope mapping using 11 antibodies, which recognized different regions of
partially folded N-segment (amino acid 1-23) and α1 helix (amino acid 24-50) [81, 95].
Following activation by BID, epitopes located on N-terminal and α1 helix were exposed
suggesting dissociation of α1 helix from protein core. Cysteine mutations were made on
α1 and α2 helices and then crosslinked through disulfide bond formation. These
constructs were impaired in cyt c release assays supporting the role of α1 helix
dissociation in mitochondrial poration. Limited proteolysis experiments using proteases
such as calpain and trypsin, which recognize exposed region of N-terminus strengthened
α1 helix dissociation as a requirement for mitochondrial poration [22, 23]. Recent crystal
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structure of rationally designed inhibitory BIM peptides (BIM H3PC) containing nonnatural amino acid demonstrated that pentyl carboxylate group establishes tight
electrostatic interactions with R42 on α1 helix [80]. (Figure 2-2). It was also
demonstrated that these “glue-like” interactions kept α1 helix in closed conformation and
blocked BAK activity in liposome permeabilization and cyt c release assays. All these
combined studies suggest role of α1 helix dissociation in BAK activation during
mitochondrial poration.
Formation of “BH3-in-groove” BAK Symmetric Homodimer
Earlier observation that BH3 domains of proapoptotic proteins engaged
hydrophobic groove of prosurvival guardians prompted the field to explore the
mechanism of BAK homodimer and heterodimer formation through similar mechanism
[96, 97]. Biochemical evidence suggested that α2 helix (BAK BH3 domain) exposure and
its subsequent interaction with hydrophobic groove of another BAK monomer is a
necessary step required for mitochondrial apoptosis [98]. In this study, 16 BAK BH3 and
groove mutants were designed and stably expressed in mammalian BAK and BAX
double knock out mouse embryonic fibroblasts (MEFs). Majority of the mutants failed to
mediate apoptosis upon exposure of apoptotic stimuli indicating critical role of BH3
domain and hydrophobic groove in apoptosis. Formation of disulphide-bond dimer
between juxtaposed α2 helix and α3 or α5 residues (M71C: K113C, M71C: H99C) upon
tBID treatment also suggested the importance of “BH3-in-groove” interaction. Following
this biochemical observation, structural evidence were proposed to better understand the
“BH3-in-groove” interaction. Inspired from partial α2 - α5 BAX core domain dimer
crystal structure, similar strategy was applied to obtain BAK core domain dimer structure
[92, 99]. In this strategy, α2 - α5 partial construct of BAK was fused to C-terminus of
Green Fluorescent Protein (GFP) to improve expression and then crystallized as a
tetramer where two GFP dimers were associated with two BAK core domain dimers
(Figure 2-3A). BAK core domain dimer structure revealed interaction of α2 of one
molecule of BAK with α3 - α5 region of partner BAK molecule suggesting “BH3-ingroove interaction”. Six hydrophobic residues of α2 helix (T70, M71, V74, L78, I81, and
I85) occupied equivalent pockets in the hydrophobic groove at each end of the core
dimer. Dimer formed was amphipathic in nature and helices α4 and α5 were rich in
aromatic residues. Due to aromatic nature of these helices and curvature of this dimer,
when looked through side view, it was predicted that α4 and α5 helices may interact with
outer mitochondrial membrane (Figure 2-3B). Crosslinking of cysteine mutants D84C
and R88C in BAK expressed in BAK and BAX knockout MEFs further validated
formation of “BH3-in-groove” dimer [92]. These studies along with earlier published
biophysical and biochemical evidence with BAX have supported “BH3-in-groove”
interaction model that may be relevant for mitochondrial poration [100, 101].
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Figure 2-2.
BAK.

Crystal structure of inhibitory BIM H3PC peptide in complex with

A) Pentyl carboxylate functional group introduced on the 3rd position of the BIM peptide
established glue like interaction with R42 on helix α1 and blocked its dissociation.
Source: Brouwer, J.M., et al., Conversion of Bim-BH3 from Activator to Inhibitor of Bak
through Structure-Based Design. Mol Cell, 2017. 68(4): p. 659-672.
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Figure 2-3.

Crystal structure of GFP fused BAK core domain dimer.

A) Construct α2 - α5 of BAK was fused to C-terminal side of GFP construct and
crystallized as a tetramer. The helix α2 (green) of one dimer molecule engaged
hydrophobic groove or helices α3 - α5 (magenta) of partner molecule. Side view of core
dimer showing helices α4 and α5 are rich in aromatic residues.
Source: Brouwer, J.M., et al., Bak core and latch domains separate during activation,
and freed core domains form symmetric homodimers. Mol Cell, 2014. 55(6): p. 938-46.
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Formation of Higher Order BAK Oligomers
According to earlier studies, “daisy-chain” BAX and BAK oligomerization model
was proposed. This model comprises of only one asymmetric interface, where front of
one molecule interacts with back or rear side of another molecule to form oligomers [102,
103]. However, this model was not consistent with well-established symmetric “BH3-ingroove” dimer model. Therefore, secondary distinct interface was proposed, which might
form higher order oligomers of BAK following “BH3-in-groove” dimer formation.
Through cysteine crosslinking analysis, formation of >18 mer BAK oligomers through α6
helix interface suggested α6:α6 as a secondary dimer interface, which lies on the opposite
of the BH3 domain and hydrophobic groove [104]. It is not clear whether this interface
forms outside the mitochondria or inserted into the membrane. As compared to the BH3in-groove interface, the α6:α6 interface is poorly defined and not necessarily required for
BAK or BAX function. It was shown that unlike “BH3-in-groove” interface mutants of
α6 interface of BAK or BAX were not impaired in cyt c release from mitochondria [91,
98].
Pore Formation on Mitochondrial Membrane
The size, nature and mode of pore formation by oligomerized effectors has been a
long-standing question in the field despite extensive biochemical and biophysical studies.
Structural resemblance of BCL-xL, BAX and BAK proteins to pore-forming toxins like
colicins and diphtheria, specifically helices α5 and α6, suggested that pores may be
formed through insertion of these helices onto outer mitochondrial membrane, although
there are no structures of colicins bound to membranes that validated this mechanism
[104]. Nonetheless, helices α5 and α6 of BAX were shown to insert into the membrane
following apoptotic signaling in biochemical investigations [105].
Two types of apoptotic pores have been proposed for BAK and BAX [71, 106,
107]. Proteinaceous or barrel-stave pores are predicted to form by aligning helices closely
in bilayer in an arrangement, where protein molecules form the solvent-exposed surface
of the pore. Lipidic or toroidal pores, which are becoming widely accepted, are formed
by combination of both lipids and proteins promoting fusion of inner and outer bilayer
leaflets to form a continuous surface at the edge of the pore [107, 108]. It is possible that
accumulation of proteins on one membrane leaflet raises the membrane tension and
curvature to form the pore. Studies using atomic force microscopy on lipid bilayers and
electron microscopy of lipid nanodiscs associated with BAX suggested the toroidal pore
formation by incomplete coverage of protein molecules on the pore rim [109, 110]. Large
openings (>100 nm) were also observed through cryoelectron microscopy analysis of
liposomes permeablized by BAX and BAK [111, 112]. Several other biophysical
approaches also characterized BAX pores in the mitochondria from apoptotic cells and
artificial membranes. In addition, super resolution microscopy of BAX fused with GFP
revealed various size of BAX lines, rings and arcs [109, 110]. Despite evidence for BAXmediated pores, BAK-mediated pores are not well studied and requires further
exploration.
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Missing Links of Working Model of BAK Conformation Transition
1. Although several structural and biochemical evidence have been proposed to
understand BAK direct activation using BH3 domain peptides but it is not known,
how full length activator proteins are associated with effectors. Also, it is not clear
how activators are associated with effectors in the membrane environment.
2. Due to poor expression of full length effector proteins, majority of the structural
studies to understand BAK activation mechanism have been performed using
truncated version of transmembrane domain (helix α9). However, it is not clearly
understood, how effectors are organized structurally in the context of transmembrane
domain. In previous studies, full length BCL-xL protein have been studied to some
extent using solid state NMR in artificial nanodisc or liposome model system [96,
113, 114]. Also, full length BAK protein has been expressed by mutating few
residues of transmembrane domain which significantly decreased expression and
solubility [93].
3. In last two decades, it is well established that dissociation of α1 helix is an early
activation step for BAK or BAX conformation transition but structural basis of how
α1 helix is rearranged with respect to other helices is not fully understood. By
comparing the different conformations of α1 helix while BAK is undergoing
activation may form the basis to understand direct BAK activation.
4. Similar to BCl-xL domain swapped dimer, BAX and BAK domain-swapped dimers
were produced in the presence of detergent to facilitate crystallization in complex
with BH3 peptides. Formation of BAK domain swapped dimer has been considered
an additional step for BAK conformation transition, whereby core (α2 - α5) and latch
(α6 - α8) domains separate following direct activation by BH3-only initiators. BCLxL and BAK or BAX domain swapped dimers are considered as “off pathway”
intermediates with no physiological relevance as their in vivo and in vitro occurrence
has not been verified. Domain-swapped dimer structure could be a consequence of
high basic pH, detergents, construct design, purification strategy or crystallization.
5. Structure of α2 - α5 core domain dimer presented partial evidence of “BH3-ingroove” interaction but it is difficult to predict how this minimal region is organized
with membrane or in the context of the other structural elements including the latch
domain and helix nine.
6. Biochemical evidence for secondary α6 - α6 dimer interface has only been supported
by low resolution crosslinking studies so far with no clear structural evidence. Nature
of pores formed by BAX are studied to some extent but BAK-mediated pore
formation still lacks complete evidence and requires further exploration. In summary,
BAK conformation intermediates studied to date are lacking functional relevance and
are not studied in the context of membrane environment.
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Proposed Model for BAK Activation in Mitochondrial Apoptosis
Based on partial evidence described earlier, we propose model to understand
BAK activation in mitochondrial apoptosis. (Figure 2-4). We sought to understand the
functional relevance of BAK conformation transition intermediates. It is well established
that BID BH3 can directly activate BAK by binding to α2 - α5 hydrophobic groove and
this direct activation step was proposed as transient hit-and-run mechanism. Upon direct
activation, α1 helix is released from rest of the protein core. However, it remained elusive
how α1 helix is rearranged in the context of other helices due to low resolution structures
or dynamic nature of BID SAHB-BAK complex NMR solution structure. In first step, we
sought to understand the rearrangement of α1 helix contacts with rest of the protein and
how this rearrangement contributes in direct activation. It is well established that BH3
domain is exposed upon apoptotic stimuli and forms “BH3-in-groove dimer”. We
hypothesize that upon α1 helix release, α2 helix is exposed which may interact with
another dormant BAK monomer. α2 helix interaction with another dormant BAK
monomer would possibly amplify activation of BAK to initiate mitochondrial poration.
Here in this study we termed this process as “BAK auto activation”. We sought to prove
the hypothesis of BAK autoactivation, which may serve as an additional activation step
and probably cooperate with direct BAK activation to amplify apoptotic signaling.
Research Questions Based on the Proposed Model
1. How can we gain a better understanding of direct BAK activation and specific
molecular interactions between BID and BAK?
2. What is the structural-basis of α1 helix destabilization in direct BAK activation?
3. Does the α2 helix, once exposed in active BAK, act as an activator of dormant
BAK in addition to forming “BH3-in-groove” dimer?
4. How can we initiate or inhibit mitochondrial poration by directly targeting BAK?
Hypotheses
1. α1 helix dissociation and rearrangements of electrostatic network at the base of
the hydrophobic groove of the BAK may form the basis for direct BAK
activation.
2. Following BID-induced BAK direct activation step and α1 helix dissociation,
BAK may be self-activated upon α2 helix exposure.
3. Direct activation and autoactivation of BAK may cooperate with each other to
amplify activation and subsequent mitochondrial poration.
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Figure 2-4.

Proposed model for BAK activation in mitochondrial apoptosis.

Dormant BAK localizes onto outer mitochondrial membrane. BID BH3 directly activates dormant BAK through “hit-and-run”
mechanism. Direct activation triggers release of α1 helix from protein core which subsequently exposes BH3 domain or α2
helix. We hypothesize that exposed α2 helix might associate with adjacent dormant BAK monomer to amplify apoptotic
signaling.
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Research Aims
Aim-1 To identify the specific molecular determinants required for transient direct
BAK activation.
Aim-2 To understand the significance of BAK autoactivation as a downstream step
to amplify mitochondrial apoptosis.
Aim-3 To understand the significance of small molecules to probe BAK activation
mechanism.
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CHAPTER 3.

MATERIALS AND METHODS

Cloning, Recombinant Protein Expression and Purification
WT MEAS-BAK and MEAS-BAK Mutants
For liposome permeabilization assay, C terminus-truncated recombinant human
wildtype BAK containing C-terminal 6× Histidine tag (WT MEAS-BAK H6) was
produced as described earlier [22, 89] . Site directed mutagenesis was performed
according to the QuikChange II XL (Agilent) manufacturer’s protocol using the WT
MEAS-BAK pRL574-ampicillin (Amp) expression plasmid as template to generate α1
helix, BAK BH3 domain (α2 helix) and hydrophobic groove (α3 and α5 helices) mutants.
WT and BAK mutant plasmids were transformed into XL10-Gold ultra-competent cells
(Agilent Technologies) using the standard transformation protocol and plated onto Amp
containing Luria-Bertani (LB) plates for positive colony screening. Cultures of three to
four individual colonies for each genotype were grown overnight (O/N) at 37 °C in 2.5
mL - 5 mL of medium (LB) supplemented with 0.1 mg/ml of Amp. Expression plasmid
then extracted for each genotype using miniprep kit (QIAGEN) and sent it for sequencing
at Sanger sequencing facility at St. Jude. Plasmid with correct genotype sequence was
then transformed again in E. coli T7 Express pLac I/Y cells (New England Biolabs) and
colonies were grown in 100 ml LB cultures. Two liter (2L) batches of LB cultures were
grown in 4L flasks by inoculating O/N minicultures and grown to an OD (600 nm) of
~1.0 at 37 °C for 3-4 hours and 1 mM IPTG was then added to express the protein O/N at
21 °C. The following morning, cells were harvested by centrifugation at 3200×g for 30
mins and were resuspended in N buffer (25 mM Tris pH 7.6, 150 mM NaCl and 10 mM
Imidazole). Cells were lysed by passing them three times through the Avestin
EmulsiFlex-C3 high pressure homogenizer. After centrifugation to separate insoluble
membranes, protein was purified by batch Ni2+-NTA affinity chromatography by mixing
Nickel beads with protein suspension for 30 mins and then passing it through gravity
column. BAK was eluted from the Nickel beads using 15 ml of N buffer supplemented
with 250 mM Imidazole. To further purify BAK, size exclusion chromatography (SEC)
on S200HR column (GE Healthcare) was performed on AKTA Pure (GE Healthcare) or
AKTA Start (GE Healthcare) chromatography systems. Pure fractions from S200 HR
chromatography were confirmed by Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE), pooled, buffer exchanged to 20 mM HEPES (pH 7.0), 2
mM DTT and concentrated by 3-4 cycles of centrifugation in Amicon centrifugal filters
(Millipore), and stored in -80 °C. The molecular masses of WT and mutant BAK proteins
were confirmed by intact mass spectrometry within the Center for Proteomics and
Metabolomics at the St. Jude Hartwell Center for Bioinformatics and Biotechnology
(herein referred to as the Hartwell Center).
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WT TEV BAK and TEV BAK G184C C166S
For structure determination, C terminus-truncated recombinant human wild type
MEAS-BAK without the C-terminal histidine tag was cloned into pNIC28-Bsa4 vector,
which provides N-terminal His6-tag cleavable by Tobacco Etch Virus (TEV) protease. An
additional TEV site was cloned before amino acid position 21 of BAK. The construct was
expressed in E. coli T7 Express pLac I/Y cells and grown by following similar steps as
described for MEAS-BAK constructs as described above. After S200 HR SEC step, the
His-tag was cleaved off by incubating concentrated protein with 0.2 mg/ml final
concentration of TEV protease and 10 mM DTT (final conv.) O/N at room temperature
(RT). BAK was further purified after buffer exchange in 25 mM Sodium Acetate (pH
5.0), by cation exchange chromatography using SPFF column (GE HealthCare) on
AKTA Pure. WT TEV BAK (residues 22-186) protein was eluted from the column using
the buffer containing 25 mM Sodium Acetate (pH 5.0), and 250 mM NaCl. TEV BAK
G184C C166S was expressed, and purified similar to WT TEV BAK. The purity of WT
and G184C C166S proteins was confirmed by SDS-PAGE. Proteins were buffer
exchanged in 20 mM HEPES (pH 7.0), 2 mM DTT, and stored in -80 °C.
15N-labelled

cBAK and WT TEV BAK

15

N-labelled WT MEAS-BAK was expressed in MOPS-based medium
supplemented with 15NH4Cl [115], in E. coli T7 Express pLac I/Y cells and purified as
described for MEAS BAK constructs. After S200HR SEC step, 15N-labelled WT MEASBAK was incubated with μI-II calpain protease, 2mM CaCl2 and 10 mM DTT for 24 hr 48 hrs at room temperature to cleave 14 residues at the N terminus and the C-terminal
His6 tag (residues 15-186, cBAK) [89]. Protein was further purified by MonoQ (GE
HealthCare) anion exchange chromatography. Purified 15N-labelled cBAK was buffer
exchanged to 20 mM phosphate (pH 6.8), 2 mM DTT, and stored in -80 °C for
subsequent two dimensional nuclear magnetic resonance spectroscopy (2D-NMR)
analysis.
GST-BAK
For competitive fluorescence polarization assays, GST-BAK previously cloned in
pGEX derivative vector pRL296, was expressed similar to other BAK proteins described
above and purified using glutathione agarose resin (Goldbio) and S200HR SEC before
being buffer exchanged in 20 mM HEPES (pH 7.0), 2 mM DTT for storage at -80 °C.
Site Directed Mutagenesis
In order to introduce mutations in WT MEAS BAK and TEV BAK, 25-36
nucleotide long primers were designed using Primer Design webserver from Agilent
Technologies (Table 3-1). Following the manufacturer’s instructions of QuikChange II
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Table 3-1.

List of primers for BAK mutants.

Mutant Name
MEAS-BAK M71A
MEAS-BAK V74A
MEAS-BAK L78A
MEAS-BAK I81A
MEAS-BAK I81R
MEAS-BAK D83A
MEAS-BAK I85A
MEAS-BAK I85R
MEAS-BAK Y89A
MEAS-BAK Y89G
MEAS-BAK F93A
MEAS-BAK F93G
MEAS-BAK Q94A
MEAS-BAK R127A
MEAS-BAK R137A
MEAS-BAK R42A
MEAS-BAK E46A
MEAS-BAK N86A
MEAS-BAK D90A

Vector
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574
pRL574

Forward Primer
5'-aacctagcagcaccgcggggcaggtgggac-3'
5'-catggggcaggcgggacggcagc-3'
5'-ggtgggacggcaggccgccatcatcggg-3'
5'-ggcagctcgccatcgccggggacgacatca-3'
5'-acggcagctcgccatcaggggggacgac-3'
5'-cgccatcatcggggccgacatcaaccgac-3'
5'-catcatcggggacgacgccaaccgacgctatgac-3'
5'-catcatcggggacgacaggaaccgacgctatgactc-3'
5'-cgacatcaaccgacgcgctgactcagagttccag-3'
5'-cgacatcaaccgacgcggtgactcagagttccag-3'
5'-gacgctatgactcagaggcccagaccatgttgcagc-3'
5'-gacgctatgactcagagggccagaccatgttgcagc-3'
5'-gctatgactcagagttcgcgaccatgttgcagcacc-3'
5'-ggcatcaattggggcgctgtggtggctcttct-3'
5'-gggcttcggctacgctctggccctacac-3'
5'-ccgcagctacgttttttacgcccatcagcaggaac-3'
5'-ccgccatcagcaggcacaggaggctgaag-3'
5'-catcggggacgacatcgcccgacgctatgactca-3'
5'-atcaaccgacgctatgcctcagagttccagacc-3'
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Reverse Primer
3'-ttggatcgtcgtggcgccccgtccaccctg-5'
3'-gtaccccgtccgccctgccgtcg-5'
3'-ccaccctgccgtccggcggtagtagccc-5'
3'-ccgtcgagcggtagcggcccctgctgtagt-5'
3'-tgccgtcgagcggtagtcccccctgctg-5'
3'-gcggtagtagccccggctgtagttggctg-5'
3'-gtagtagcccctgctgcggttggctgcgatactg-5'
3'-gtagtagcccctgctgtccttggctgcgatactgag-5'
3'-gctgtagttggctgcgcgactgagtctcaaggtc-5'
3'-gctgtagttggctgcgccactgagtctcaaggtc-5'
3'-ctgcgatactgagtctccgggtctggtacaacgtcg-5'
3'-ctgcgatactgagtctcccggtctggtacaacgtcg-5'
3'-cgatactgagtctcaagcgctggtacaacgtcgtgg-5'
3'-ccgtagttaaccccgcgacaccaccgagaaga-5'
3'-cccgaagccgatgcgagaccgggatgtg-5'
3'-ggcgtcgatgcaaaaaatgcgggtagtcgtccttg-5'
3'-ggcggtagtcgtccgtgtcctccgacttc-5'
3'-gtagcccctgctgtagcgggctgcgatactgagt-5'
3'-tagttggctgcgatacggagtctcaaggtctgg-5'

XL kit (Agilent Technologies), 25 µl of total volume was prepared for site-directed
mutagenesis reactions for each BAK mutant. 2.5 µl of 10× reaction buffer, 1.5 µl of
Quick solution, 0.5 µl of dNTPs, 125 ng of each forward andreverse primers, 10 ng of
double stranded DNA template, 0.5 µl Pfu Turbo DNA polymerase and distilled
deionized water (ddH2O) to a final volume of 25 µl were mixed in PCR tubes. The kit
instructions were followed to set up the thermocycler (Invitrogen) to run the site-directed
mutagenesis PCR amplification reaction. After amplification, 1 μl of Dpn I restriction
enzyme (10 U/μl) was added to cleave DNA containing methylated adenine. 2 μl of the
Dpn I digestion PCR reaction was transformed into the XL10-Gold ultracompetent cells
(Agilent Technologies) and plated onto LB agar plates with selective antibiotic for colony
screening. Three to four individual colonies were grown and plasmid was extracted as per
Qiagen’s Miniprep manufacturer’s instructions. DNA sequences were verified at Sanger
sequencing at the Hartwell Center.
Peptide Synthesis
The BH3 peptides were synthesized at the Hartwell Center.
Liposome Permeabilization Assay
Liposome permeabilization assay was performed using MEAS-BAK H6 as
described previously [87, 116]. Lipid films of composition similar to that of the outer
mitochondrial membrane were prepared by mixing the following lipids: 40.9%
phosphatidylcholine, 26.6% phosphatidylethanolamine, 9.1% phosphatidylinositol, 8.3%
phosphatidylserine, 7% Cardiolipin, and 8% of the unnatural nickel chelating lipid (1,2Dioleoyl-sn-Glycero-3-[N-(5-amino-1-carboxypentyl)iminodiacetic-acid)-succinyl], to
facilitate recruitment of His-tagged BAK. Large unilamellar vesicles (LUVs) were
prepared by resuspending lipid films in LUVs buffer (10 mM HEPES pH 6.8, 200 mM
KCl and 5 mM MgCl2). Mixture of 12.5 mM fluorophore; [8-aminonaphthalene-1, 3, 6trisulfonic acid, disodium salt (ANTS)] and 45 mM quencher [p-xylene-bispyridiniumbromide (DPX)] were encapsulated within LUVs by extrusion through 200 nm
pore size polycarbonate membrane. The LUVS were separated from excess free
ANTS/DPX by passing through S500HR SEC column, and stored at 4 °C in the dark.
Liposomes permeabilization reactions were performed by incubating LUVs with
MEAS-BAK H6 and BH3 peptides at varying concentrations in 96-well black flat bottom
plates (Costar) on ice. ANTS release upon liposome permeabilization was monitored at
37 °C for 90 mins using a CLARIOstar microplate reader (BMG Labtech) with excitation
and emission wavelengths set at 360 nm and 530 nm, respectively. Fluorescence data was
normalized relative to maximum and minimum fluorescence induced by 2.5 % CHAPS
detergent and buffer controls, respectively. Liposome permeabilization was quantified by
integrating area under the curve (AUC) of normalized fluorescence kinetic traces using
the Simpson’s rule [87].
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Cytochrome c Release Assay
Cytochrome c (cyt c) release or MOMP assay was performed according to our
previously published protocols [23]. Briefly, livers enriched in mitochondrias were
isolated from C57BL/6 and BAK knockout mice by abdominal surgery and stored in 1×
PBS in 50 mL conical tube. Mouse livers were then rinsed with 25 mL of 1× PBS 3-4
times to eliminate excess blood and fat tissues. Livers kept on ice were sliced thinly using
a blade and transferred into 10 mL mitochondrial isolation buffer (MIB) in a glass tube
and subjected to homogenization. MIB buffer was composed of 200 mM mannitol, 68
mM sucrose, 10 mM HEPES (pH 7.4), 10 mM KCl, 1 mM EDTA and 1 mM EGTA
supplemented with Complete Protease Inhibitor (Roche). Homogenized livers were then
transferred to a 15 mL round bottom tube and subjected to multiple rounds of differential
centrifugation using BioShield 1000 rotor (Thermofisher Scientific) to isolate
mitochondria. Serial dilutions of peptides or compounds were prepared in 96-well plates
and incubated with 50 µl of isolated mitochondrias at 37 °C for 90 mins. In order to
separate pellets and supernatants, assay plates were centrifuged at high speed of 6300
rpm using HighPlate 6000 rotor (Thermofisher Scientific). Supernatants and pellets were
then resuspended in SDS sample buffer for SDS-PAGE analysis. To detect cyt c release
immunoblot analysis was performed on supernatant and pellet fractions using 1:2000
diluted mouse monoclonal anti-cyt c primary antibody (BD Biosciences, Cat No. 556432)
and 1: 2000 diluted anti-mouse secondary antibody (GE Healthcare, Cat No. NA931V).
Competitive Fluorescence Polarization Assay
Competitive fluorescence polarization (FP) assays, which measures the
displacement of fluorescent peptide, BID BH3 stabilized alpha helix of BCL-2 proteinFluorescein (SAHB-F) from GST-BAK, were performed in 384-well Greiner black
polystyrene plates (Sigma-Aldrich). Master mix of 50 mM Tris-HCl (pH 7.5), 50 mM
KCl, 0.1 mg/mL BSA, 2 mM DTT, 0.005% Tween-20, 10 nM BID BH3 SAHB-F and 1
μM GST-BAK was dispensed in plates using multichannel pipette (Integra). Peptides
were then pin transferred using Biomek FX (Beckman Coulter Life Sciences, IN) to
achieve final concentration of 500 μM-0.2 μM in 20 μL final volume. Plates were briefly
centrifuged to remove air bubbles and incubated for 60 mins at room temperature and
then polarization intensity was measured on CLARIOstar microplate reader (BMG
Labtech) with excitation and emission wavelength set at 485 nM and 535 nM,
respectively. Free peptide BID BH3 SAHB-F and GST-BAK bound BID BH3 SAHB-F
in each plate were considered as positive and negative controls, respectively. Z’-values
were derived using the equation, {1-[3(stdevL+stdevH)/(averageH-averageL)]}where L
was free BID BH3 SAHB-F peptide control and H is the GST-BAK bound SAHB-F
peptide control. Calculated Z’-values > 0.8 indicated excellent assay performance
(Figure 3-1). Percent inhibition of polarization intensity was processed and visualized
using automated software Robust Investigation of Screening Experiments (RISE)
developed at St. Jude in the Pipeline Pilot platform (Accelrys v.8.5.0). FP assays were
performed at least three times in triplicates. Dose response curves and IC50 values were
plotted in RISE, Microsoft Excel and GraphPad Prism v7.
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Figure 3-1.

Qualitative analysis of FP assay plates.

Z’ values are derived by considering free fluorescent SAHB-F peptide (probe) positive
and negative (GST BAK bound to SAHB-F) controls.
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Two-dimensional (2D) Nuclear Magnetic Resonance (NMR) Binding Titrations
Two-dimensional 15N-1H TROSY (Transverse relaxation optimized spectroscopy)
NMR experiments were performed with 50 μM 15N-labeled WT cBAK or TEV BAK
with titration of unlabeled WT and mutant BID and BAK BH3 peptides. Peptides were
dissolved in deuterated DMSO (DMSO-d6) and diluted at six concentrations (50, 100,
200, 400, 600, and 800 μM). Samples were prepared in NMR buffer containing 20 mM
phosphate buffer (pH 6.8), 10% D2O, and 2.5 μM deuterated DTT. DMSO titration
controls were performed with each set of titration experiments. NMR spectra were
collected using Bruker Avance 600 MHz spectrometers at 298K. Data was processed in
TopSpin (Bruker) and analyzed in CARA [55]. 2D 15N-1H chemical shift perturbations
(CSPs) was calculated using the equation [(Δ1H ppm) 2 + 0.2× (Δ15N ppm)2]1/2 [117].
Isothermal Titration Calorimetry Binding Assay
In ITC binding assay, thermodynamic binding parameters for binding of various
BID BH3 peptides to WT TEV BAK and I81R TEV BAK mutant were measured using a
MicroCal auto-iTC 200 (Malvern Instruments). Protein samples were buffer exchanged
into 20 mM HEPES, 100 mM NaCl and 1 mM TECEP using Slide-A-Lyzer Dialysis
Cassettes prior to the experiment. Titrations were performed by first injecting 0.5μl of
250 or 500 μM BID BH3 peptides into a solution of 20 or 50 μM BAK followed by
additional 2 μl injections. Experiments were carried out at 25 °C. Results were analyzed
using Origin software (OriginLab) provided by MicroCal. Binding constants (KD) and
thermodynamic parameters were calculated from the average of two or three individual
titrations by fitting the data to a single site binding model using a nonlinear least squares
fitting algorithm.
Surface Plasmon Resonance Binding Assay
SPR experiments were conducted at 20° C using a Pioneer FE optical biosensor
(ForteBio). 6× His tagged BAK (WT MEAS BAK) was immobilized on polycarboxylate
hydrogel-coated gold chips preimmobilized with nitrilotriacetic acid (HisCap chips;
ForteBio). The chip was primed in chelating buffer (10 mM HEPES pH 7.4, 150 mM
NaCl, 50 µM EDTA, 0.005% Tween20) and was preconditioned at 10 µL/min with three
60s injections of wash buffer (10 mM HEPES pH 8.3, 150 mM NaCl, 350 mM EDTA,
0.05% Tween20) and one 60s injection of chelating buffer before being charged with a
60s injection of 500 µM NiCl2 in chelating buffer. After priming into binding buffer (20
mM HEPES pH 8.0, 200 mM NaCl, 1 mM TCEP, 0.01% Tween20), BAK was injected
until ~500 RU of protein were captured. One flow cell on the chip was charged with Ni2+
without adding protein to be used as a reference cell. Peptides were prepared in binding
buffer as a three-fold dilution series at a maximum concentration of 100 µM for
M(3)M(5) BID BH3 and WT BID peptides and of 10 µM for all other peptides and were
injected in triplicate for each concentration at a flow rate of 75 µL/min. A series of
buffer-only (blank) injections was included throughout the experiment to account for
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instrumental noise. The peptides fully dissociated from the protein surfaces, eliminating
the need for a regeneration step. The data were processed, double-referenced, solvent
corrected and analyzed using the software package Qdat (version 4.3.1.2, ForteBio).
Kinetic rate constants and affinities were determined by fitting the data to a 1:1
interaction model.
Covalent Complex Formation of BH3 Peptides to BAK
M(3)W(5) BID BH3 or WT BAK BH3GGC-G184C C166S TEV BAK covalent
complexes were prepared for structure determination and thermal shift assays (TSA) by
incubating 10 mg/mL protein (~500 μM) with 2.5-10-fold molar excess of M(3)W(5)
BID BH3-GGC or BAK BH3-GGC peptides in 20 mM HEPES buffer (pH 7.5-8.0) at 24
hr - 72 hrs at room temperature. Excess free peptide was separated by MonoS cation
exchange or S200GL SEC. The purity of complexes were assessed on SDS-PAGE
analysis.
X-Ray Crystallography
The Covalent M(3)W(5) BID BH3-BAK Complex
Purified M(3)W(5) BID BH3GGC-G184C C166S TEV BAK (10 mg/ml)
complex (referred to as M(3)W(5) BID BH3-BAK complex) was incubated with 500 μM
CuSO4 as an additive before crystallization. Crystals grew in 15% PEG 4000, 0.2 M
NaCl, 0.1 MES (pH 6.5). Crystals were cryo-protected in 1:1 paratone: paraffin oil
mixture and stored in liquid nitrogen. X-ray data was collected at SERCAT 22-ID
beamline. Diffraction images were processed and scaled in HKL2000 [118] and prepared
for structure determination in CCP4 [119, 120]. The structure was solved by molecular
replacement in PHENIX [121] using published BAK structures, apo BAK (PDB: 2IMT)
and the BIMH3PC: BAK complex (PDB: 5VWZ) as templates. Refinement was
performed in PHENIX and model building in COOT [122]. Structure visualization,
illustration, and rendering for all structures were done in PyMOL molecular graphics
system.
W(3)W(5) BID BH3-TEV BAK Complex
To prepare the non-covalent W(3)W(5) BID BH3:TEV BAK complex, WT TEV
BAK (10 mg/mL) was incubated with 500 μM CuSO4 for 2-3 hrs and then 4-fold molar
excess of W(3)W(5) BID BH3 peptide was added before crystallization. Crystals grew in
0.2 M potassium sodium tartrate and 20% (w/v) PEG 3350 and then cryo-protected in 1:1
paratone: paraffin oil mixture and stored in liquid nitrogen. X-ray data was collected at
SERCAT 22-ID beamline at 100K. Diffraction images were processed and scaled in
HKL2000, and then reformatted for structure determination in CCP4. The structure was
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solved by molecular replacement in PHENIX using the M(3)W(5) BID-BAK complex
(PDB: 4UK8) as a template, further refined in PHENIX, and built in COOT.
The Covalent BAK BH3-BAK Complex
WT BAKGGC-G184C C166S TEV BAK complex (referred to as BAK BH3BAK complex) was incubated with 500 μM CuSO4 as an additive before crystallization.
Small rod crystals (6-8 μm) grew in 0.1 M MES pH 6.5, 0.5 M Ammonium Sulfate
followed by cryo-protection with 25% glycerol in mother liquor and stored in liquid
nitrogen. X-ray data was collected at FMX beamline at the National Light Source II,
Brookhaven National Laboratories, specialized for micro-crystals. Diffraction images
were processed with XDS [123]. The structure was solved by molecular replacement with
PHENIX using the M(3)W(5) BID BH3GGC-BAK complex as a template. The structure
was refined using PHENIX and REFMAC and the model was built in COOT.
Thermal Shift Assay
Thermal Shift Assay (TSA) were carried out in 20 μL reactions in 384-well PCR
plates (Cat# AB1384,Thermo Fisher Scientific) in 20 mM HEPES (pH 7.0), 150 mM
NaCl, 2 mM DTT, 5× SYPRO TM Orange dye and 0.25 mg/mL purified BAK. Prepared
master mix was dispensed in assay plates using multichannel pipette (Integra) and then
sealed with MicroAmp Optical Adhesive followed by incubation for 2 min - 5 min at RT.
To remove air bubbles plates were briefly centrifuged at 1000×rpm. Assay plates were
subjected to 25 °C - 99 °C thermal gradient with 1 degree/minute increment and
fluorescence was recorded using Applied Biosystems Quant Studio 5. Experiments were
performed at least three times in quadruplicates for each sample. Data was processed in
RISE, Microsoft Excel, and GraphPad Prism.
Glutaraldehyde Crosslinking of BAK Mutants
Glutaraldehyde (GA) crosslinking of WT and mutant MEAS-BAK was performed
using 50 nM - 200 nM protein in 20 mM HEPES (pH 7.0), 2 mM DTT ± liposomes ±
WT BID BH3 peptide. Samples were incubated at 37 °C for 90 min followed by addition
of 0.05% GA crosslinker and additional incubation for 2 hr at RT. To stop the reaction,
samples were quenched in 50 mM TRIS pH 8.0. Samples were analyzed for crosslinking
patterns by SDS-PAGE and immunoblotting using Anti-BAK Ab-1 (Calbiochem
Cat#AM03) mouse monoclonal antibody in 1:1000 dilution and anti-mouse IgG ECL
secondary antibody in 1:2000 dilution (GE Healthcare Cat#NA931V).
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Ligand-based NMR Fragment Screening
Subsets of the St. Jude fragment library, including Maybridge, Maybridge
Fluorinated, Three Point Pharmacophore and 3D were screened by ligand- based NMR.
Samples were prepared by dispensing mixtures of 4-5 fragments at 200-400 μM final
concentration into 20 mM phosphate buffer (pH 6.8), 10% D2O, and deuterated DTT ± 5
μM cBAK in 5 mm NMR tubes using Gilson 215 liquid handler (Bruker). Data
acquisition was performed at 298 K on one 80-tube rack at a time using a Bruker Avance
600MHz spectrometer equipped with SampleJet sample changer. For fragment screening
experiments, one-dimensional (1D) 1H, Spin-lockand WaterLOGSY (Water-Ligand
Observed via Gradient Spectroscopy) NMR spectras were recorded for compound pools
without and with protein. Data was processed and analyzed using Topspin 3.2 software.
In WaterLOGSY experiment, fragment hits were identified by a flip in Nuclear
Overhauser Effect (NOE) phasing between protein-fragment complex compare to
unbound fragments [124]. Spin-lock relaxation-based fragment hits were identified by
observing the enhanced relaxation of NMR signals for protein-fragment complex
compared to fragments alone [125]. To identify the hits from the mixtures we compared
the mixture spectra with the 1D spectra of individual fragments.
Statistical Analysis
For each experiment data was plotted as mean of triplicate or quadruplicate
measurements with error bars of standard deviation (SD). Data is combined from two to
three independent experiments as average and standard error of the mean (SEM).
Statistical analyses was performed using by one-way ANOVA, Dunnett’s or TukeyKramer multiple comparisons test with 0.05 confidence level in Graph PadPrism 7.0. For
comparisons of two groups, t-test was performed. P-values are indicated as ****
P<0.0001, *** P<0.0002, ** P<0.0021, and * P<0.0332.
Data Availability
The accession numbers for the atomic coordinates and structure factors deposited
are PDB: 6UK7, W(3)W(5) BID BH3-BAK complex; 6UK8, M(3)W(5) BID BH3-BAK
complex; and 6UK9, BAK BH3-BAK complex.
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CHAPTER 4.

RESULTS

C-Terminus of BID BH3 Is Crucial for Direct BAK Activation
In the presence of mitochondria active BAK undergoes conformational changes
that unfolds α1 helix of BAK as shown in epitope exposure and limited proteolysis
experiments [21, 22, 81, 95]. It has been proposed that activating and inactivating BH3
peptides engage the hydrophobic groove of BAK to induce cavities of variable depth that
destabilize dormant BAK [22, 80]. Based on the observation that the C-terminal end of
α1 helix is found at the bottom of these cavities near the C-terminal region of the BH3,
we hypothesized that this region has molecular determinants necessary for direct BAK
activation. To test this hypothesis, we engineered four peptides including sensitizers BH3
peptides (BMF and NOXA) and activators BH3 peptides (BIM and PUMA). First, we
overlaid the peptides sequence (Figure 4-1A) and identified the conserved positions of
all peptides (L90 and D95). Amino acid residues after second conserved position D95
were replaced by six residues ‘SMDRSI’ derived from C-terminal side of WT BID BH3
peptide (Figure 4-1B) .We investigated the activation of 50 nM BAK (MEAS-BAK∆TM-His6) by the engineered and parent peptides in Large Unilamellar Vesicle
Permeabilization (LUVP) or Liposome Permeabilization assay [87, 116]. Liposomes are
composed of the mitochondrial lipids (PC, PE, PI, PS, and CL) and the DGS-NTA (Ni)
lipid for His-tag recruitment of BAK. When BAK is activated in response to peptides it
permeabilizes liposomes releasing the fluorophore/quencher pair ANTS/DPX
encapsulated inside the liposome. An increase in ANTS fluorescence over time is an
indication of BAK activation. Liposome permeabilization is quantified as area under the
curve (AUC) of fluorescence kinetic traces (e.g. for 24-88 min time interval). The BMFBID chimera peptide induced significantly more BAK activation than BMF BH3 peptide
at all tested peptide concentrations (50, 25, 10 and 1 μM) (Figures 4-2A, B). At 10 μM
and higher doses of peptide there was no significant difference between BMF BID and
WT BID peptides in BAK activation, although at 1 μM the WT BID peptide was better
activator (Figure 4-2B). We also compared BAK activation in response to other WT and
chimeric peptides. The majority of chimeric peptides at 50 μM and 25 μM activated BAK
significantly better than the WT controls (Figure 4-3A). To validate our results, we
tested BMF BH3 and BMF BID chimeric peptides fused to a mitochondrial targeting
sequence (MTS) from NOXA [126] in MOMP assays using mitochondria purified from
livers of WT B6 mice (Figure 4-4A). These mitochondria are enriched in endogenous
BAK but exclude BAX, and therefore cyt c released in response to these peptides
indicates BAK activation. BMF BID MTS hybrid peptide induced higher extent of cyt c
release as compared to the BMF MTS peptide, evident at levels below 200 nM peptide
(Figure 4-4A). We quantified cyt c release by integrating the intensity of western blot
bands (Figure 4-4B). MOMP analysis has been performed only once. We conclude that
by replacing the C-terminal sequence of BID BH3 we convert BMF BH3 into a direct
BAK activator supporting the crucial role of this sequence in direct BAK activation in
vitro.
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Figure 4-1. Peptides designed to probe the role of C-terminal BH3 sequence in
direct BAK activation.
A) Sequence alignment of BH3 peptides highlighting conserved amino acid positions
(yellow). Chimeric BH3 peptides were designed by replacing residues after conserved D
position to SMDRSI sequence of WT BID BH3 (blue).
B) Cartoon: surface representation of the structure of BAK: BID SAHB complex (PDB:
2M5B) highlights C-terminal residues of WT BID (blue).
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Figure 4-2.

BMF BID peptide activates BAK in liposome permeabilization assay.

A) Kinetic traces of normalized liposome permeabilization measured at 37 ̊C indicates
BAK activation in response to WT BID, BMF BH3 and BMF BID. Data is represented as
mean + standard deviation (SD) of three independent experiments performed in
triplicates. Data was normalized relative to permeabilization by 2.5% CHAPS detergent.
B) BAK activation measured in response to BMF BH3, BMF BID and WT BID peptides
is quantified as area under the curve (AUC) for kinetic traces in (A). Data are represented
as mean + SD of three independent experiments performed in triplicates.
Note: Statistical p-values are **** P<0.0001, *** P<0.0002, ** P<0.0021, and *
P<0.0332 measured using one-way ANOVA with the Tukey-Kramer multiple
comparisons test.
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Figure 4-3. BAK activation by chimeric BH3 peptides in liposome
permeabilization assay.
A) BAK activation measured in response to the peptides from Figure 4-1A. Liposome
permeabilization AUC data are represented as mean + SD of three independent
experiments performed in triplicates.
Note: Statistical p-values are **** P<0.0001, *** P<0.0002, ** P<0.0021, and *
P<0.0332 measured using one-way ANOVA with the Tukey-Kramer multiple
comparisons test.
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Figure 4-4. BAK activation by mitochondrial-targeted BMF BID peptide in
MOMP assays.
A) Sequence alignment of BMF BH3 and BMF BID peptides designed by fusion of
mitochondrial targeting sequence (MTS) at C-terminus. MOMP assay was performed to
assess the activity of BAK in response to two peptides. Western blot images represent the
release of cyt c from mitochondria (pellet) into supernatant when incubated in the
presence of peptides at 37 ̊C for 1 hour. It is representative of only one time experiment.
B) Intensity of western blot bands were integrated to estimate the percent of cyt c
released in the supernatant.
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Scanning Mutagenesis of BID BH3 Peptide to Probe Hydrophobic Groove Sub
Pockets
It has previously been established that BID BH3 activator protein engaged
hydrophobic groove of BAK through seven hydrophobic interaction sites [22, 92] named
(0)-(5) here (Figure 4-5A). Previous mutagenesis studies of hydrophobic BID BH3
residues to alanine or glycine confirmed that these interactions contribute to affinity and
BAK activation [22]. To explore the depth and plasticity of the activation groove, we
replaced the hydrophobic residues at each positions (0)-(5) to larger hydrophobic residues
including: Methionine (M), Phenylalanine (F), Tyrosine (Y), and Tryptophan (W)
(Figure 4-5B). We investigated the activity of BAK in response to WT BID and 15 BID
monosubstituted mutant peptides using liposome permeabilization assays. W(1), M(2),
F(2), Y(2), W(2), W(3) and F(4) peptides induced significantly less BAK activation as
compared to WT BID while other peptides induced either equivalent activation or more
as compared to WT BID, specifically M(3), F(3), Y(3) and W(4) being the most active
peptides. (Figure 4-5C).
We measured the binding affinities of monosubstituted BID peptides using
competitive fluorescence polarization (FP) assays and two-dimensional nuclear magnetic
resonance spectroscopy (2D NMR). The FP assay measures the displacement of BID
SAHB-F from GST-tagged BAK by BID peptides. Dose-dependent decrease in FP signal
indicates binding, which is represented as percent inhibition of FP signal (IC50) (Figure
4-5D). Peptides mutated at positions (1) and (2) are severely impaired in binding,
whereas all other peptides bound similar to or better than WT BID (Table 4-1). The
results of 2D NMR binding assays correlated well with those of the FP assay.
Specifically, W(1), M(2), F(2), Y(2), W(2) peptides exhibit impaired binding to BAK
revealed by small CSPs, while the other peptides bind similar to or better than WT BID
inducing widespread CSPs in BAK, with many in the intermediate exchange NMR
regime (broad peaks, too weak to be detected) (Figure 4-6). We qualitatively mapped the
CSPs of each BAK residue induced by 800 μM peptide (Figure 4-7).
Based on functional and binding data, we can conclude that the sub pockets at
positions (1) and (2) of hydrophobic groove are shallow and cannot accommodate larger
hydrophobic residues, while those at (0), (3)-(5) are deep and can accommodate larger
hydrophobic residues. These results have rationally informed the design of di and tri
substituted BID peptides as well as drug discovery strategies for targeting BAK.
Biochemical Basis of Transient Direct BAK Activation
It has previously been proposed that BID BH3 binds to BAK weakly (Kd ~10 μM)
and transiently activates it. [22, 127, 128]. Due to weaker affinity of BID BH3 peptide
and BAK, the mechanism has been proposed as a “hit-and-run”, which has not been
elucidated clearly due to the difficulty in capturing these complexes at high resolution.
Our observations that some of the monosubstituted BID peptides, such as M(3) and W(5)
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Figure 4-5. Investigation of BID BH3 peptides interaction with BAK hydrophobic
groove sub pockets.
A) Cartoon: surface representation of the structure of BAK: BID SAHB complex (PDB:
2M5B). WT BID has hydrophobic amino acid residues at positions (0)-(5).
B) Sequence alignment of WT and 15 mutant BID BH3 peptides. Smaller hydrophobic
amino acid residues at positions (0)-(5) of WT BID BH3 peptide were replaced by larger
hydrophobic amino acid residues M, F, Y and W.
C) BAK activation in response to BID BH3 peptides in (B) measured in liposome
permeabilization assay and quantified as AUC. Data are represented as mean + SD of
three independent experiments performed in triplicates.
D) Fluorescence Polarization (FP) percent inhibition analysis curve for displacement of
BID SAHB-F from GST BAK by BID BH3 peptides in (B).
Note: Statistical p-values are **** P<0.0001, *** P<0.0002, ** P<0.0021, and *
P<0.0332 measured using one-way ANOVA, Dunnette’s multiple comparisons test.
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Table 4-1.
Summary of FP IC50 percent inhibition for displacement of BID
SAHB-F from GST-BAK by BID BH3 mutant peptides.
BID BH3 Peptides
WT BID

Fluorescence Polarization (FP) Assay
% Inhibition IC50 (μM)
12.8 ± 4.7

W(0) BID
W(0’) BID
W(1) BID
M(2) BID
F(2) BID
Y(2) BID
W(2) BID
M(3) BID
F(3) BID
Y(3) BID
W(3) BID
F(4) BID
Y(4) BID
W(4) BID
W(5) BID

8.1 ± 0.6
13.4 ± 3.9
124.9 ± 0.2
17.7 ± 0.2
N.D.
N.D.
N.D.
3.5 ± 0.4
11.3 ± 1.1
9.5 ± 1.9
5.8 ± 0.3
9.7 ± 1.4
6.4 ± 0.9
6.0 ± 0.6
8.7 ± 0.6

Note: N.D. = Not Determined
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Figure 4-6. 2D Nuclear magnetic resonance spectroscopy titrations of BID BH3
peptides to BAK.
Overlaid 2D 15N-1H Transverse relaxation optimized spectroscopy (TROSY) spectra for
WT cBAK (50 μM) and 16 BID BH3 peptides. Molar ratio of protein: peptides are color
coded. Peptides mutated at (1) and (2) positions demonstrated weaker binding revealed
by small chemical shifts of NMR peaks. Peptides mutated at (0), (0’), (3), (4), (5)
demonstrated stronger binding revealed by largest chemical shifts in intermediate and fast
exchange resonances.
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Figure 4-7.

NMR CSPs analysis of BID peptides binding to BAK.

2D 15N-1H CSPs of cBAK residues at 800 μM BID BH3 peptide for the titrations from
Figure 4-6. Significant fast exchange resonances (orange) are described as ≥ 1 SD above
the average between significant and insignificant CSPs (black); intermediate and slow
exchange resonances (red) were assigned CSP value of 0.1 ppm; overlapping resonances
(blue).
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BID BH3, are better binders and activators of BAK than WT BID, while other peptides
are better binders yet inhibitors of BAK activation [e.g. W(3) and F(4) BID BH3]
suggested new opportunities to modulate BAK activation and inactivation with rationally
designed BH3 ligands. We designed di- and trisubstituted BID BH3 peptides with
combinatorial mutations at (3) and (5) or (3)-(5) hydrophobic residue positions to
investigate their ability to modulate BAK activity in liposome permeabilization assay
(Figure 4-8A, B). All the peptides were able to activate BAK at 1 μM peptide
concentration. At 10 and 50 μM peptide concentration the M(3)M(5) BID BH3 activated
BAK even better than WT BID, while the M(3)W(5) BID BH3 and M(3)Y(4)W(5) BID
BH3 peptides partially activated BAK. The W(3)W(5) BID BH3, M(3)W(4)W(5) BID
BH3 , W(3)Y(4)W(5) BID BH3 and W(3)W(4)W(5) BID BH3 inhibited BAK activity
completely.
We then determined the binding constants (KD) of these peptides using Isothermal
Titration Calorimetry (ITC) (Figure 4-9, Table 4-2), which showed a significant increase
in affinity for the disubstituted peptides compared to WT BID (~22.7 μM), M(3)M(5)
BID BH3 [~4.33 μM], M(3)W(5) BID BH3 [~0.69 μM] and W(3)W(5) BID BH3 [~0.25
μM]. Therefore, large hydrophobic residues at positions (3) and (5) of BID peptide
dramatically increases binding affinity to BAK. Trisubstituted BID BH3 peptides exhibit
enhanced affinity for BAK compared to WT BID but are not better than W(3)W(5) BID
BH3. Additionally, we validated the binding of all peptides using a second assay, Surface
Plasmon Resonance (SPR), which demonstrated similar KD values as ITC (Figure 4-10).
W(3)W(5) BID BH3 demonstrated the lowest KD value, with a large association rate
constant and small dissociation constant (Table 4-3). WT BID and M(3)M(5) BID BH3
peptides, which were weak binders, demonstrated reduced association rate and greater
dissociation rate constants, respectively. The observed SPR-based association and
dissociation rates correlate well with the transient “hit-and-run” direct BAK activation
model whereby inhibitor peptides (e.g. W(3)W(5) BID BH3) dissociated from the
hydrophobic groove slowly, enforcing an inhibited BAK conformation. In contrast,
activator peptides (e.g. M(3)M(5) BID BH3) are able to readily dissociate from the
hydrophobic groove, enabling the transition of BAK into active conformation. To
calculate the percent of BAK bound by peptides (%), we used Equation 4-1.
Percent Bound (%) = [Concentration peptide/(KD + Concentration of peptide)*100]
(Eq. 4-1)
A summary of the percent bound values for the di- and trisubstituted BID BH3
peptides is given in (Table 4-4). These values suggest that 4.2 – 35.7 % peptide bound is
sufficient to activate BAK although the M(3)M(5) BID BH3 peptide was more than 90%
bound and is still a potent activator of BAK. On the other hand, the W(3)W(5) BID BH3
peptide at low and high occupancy is activating and inactivating, respectively. In
summary, in order for BAK to transition into active conformation, an activator must
dissociate from the BAK hydrophobic groove to allow downstream conformational
changes for further activation steps.
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Figure 4-8.

Transient direct BAK activation revealed biochemically.

A) Sequence alignment of BID BH3 peptides with substitutions at positions (3), (4) and
(5) to hydrophobic residues M, Y, and W.
B) BAK activation in response to BID BH3 in (A) is measured in liposome
permeabilization. AUC for 24-88 mins time interval are represented as mean + SD of
three independent experiments performed in triplicates.
Note: Statistical p-values are **** P<0.0001, *** P<0.0002, ** P<0.0021, and *
P<0.0332 measured using one-way ANOVA, Dunnette’s multiple comparisons test.
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Figure 4-9.
peptides.

Isothermal titration calorimetry of BAK binding to BID BH3

Isothermal titration calorimetry (ITC) thermograms for BAK (20-50 μM) binding to BID
BH3 peptides (250-500 μM). The top panels show the heat released following each
addition of the peptides to BAK. The bottom panels shows the integrated heat released
per mole of peptide vs. protein molar ratio. The derived thermodynamic parameters (∆G,
∆H, KD and T∆S) are summarized in (Table 4-2).
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Table 4-2.

ITC thermodynamic parameters for BAK binding to BID BH3 peptides.
BID BH3
Peptides
WT
M(3)M(5)
M(3)W(5)
W(3)W(5)
M(3)W(4)W(5)
W(3)Y(4)W(5)
W(3)W(4)W(5)

∆G
(kcal/mol)

KD (μM)

-6.34 ± 0.04
-7.32 ± 0.05
-8.41 ± 0.07
-9.02 ± 0.10
-8.29 ± 0.06
-7.51 ± 0.14
-7.84 ± 0.25

22.70 ± 1.56
4.33 ± 0.38
0.69 ± 0.88
0.25 ± 0.44
0.85 ± 0.90
3.1 ± 0.7
1.8 ± 0.7
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∆H
(kcal/mol)
-6.75 ± 0.07
-5.09 ± 0.55
-9.9 ± 1.1
-14.55 ± 1.76
-9.11 ± 0.58
-7.70 ± 0.84
-4.0 ± 0.7

T∆S
(kcal/mol)cal
0.41 ± 0.11
-2.23 ± 0.49
1.49 ± 1.18
5.53 ± 1.6
0.82 ± 0.52
0.19 ± 0.98
-3.84 ± 0.96

N
1.0 ± 0
1.0 ± 0
1.2 ± 0.15
1.05 ± 0.2
1.1 ± 0.14
1.05 ± 0.06
1.15 ± 0.07

Figure 4-10. Surface plasmon resonance analysis of BAK binding to BID BH3
peptides.
Surface plasmon resonance (SPR) sensorgrams for BAK titrated with the BID BH3
peptides. WT MEAS-BAK-H6 was immobilized on a nickel-nitrilotriacetic acid (NiNTA) sensor chip. Theoretical profiles (orange) are fitted over the raw data (black). The
derived kinetic and thermodynamic parameters are summarized in (Table 4-3).
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Table 4-3.

SPR parameters for BAK binding to BID BH3 peptides.
BID BH3
Peptides
WT
M(3)M(5)
M(3)W(5)
W(3)W(5)
M(3)Y(4)W(5)
M(3)W(4)W(5)
W(3)Y(4)W(5)
W(3)W(4)W(5)

ka (M-1 s-1)

kd (s-1)

KD (µM)

Rmax (RU)

4.19 (± 0.02) x 103
1.31 (± 0.01) x 104
6.21 (± 0.01) x 104
7.19 ( 0.01) x 104
4.57 (± 0.01) x 104
5.64 (± 0.02) x 104
4.20 (± 0.01) x 104
3.21 (± 0.01) x 104

2.61 (± 0.01) x 10-1
1.23 (± 0.01) x 10-1
3.14 (± 0.01) x 10-2
2.41 (± 0.01) x 10-2
7.11 (± 0.01) x 10-2
6.00 (± 0.01) x 10-2
3.23 (± 0.01) x 10-2
3.52 (± 0.01) x 10-2

62.3 (± 0.4)
9.34 (± 0.04)
0.506 (± 0.001)
0.340 (± 0.001)
1.56 (± 0.01)
1.06 (± 0.01)
0.768 (± 0.002)
1.10 (± 0.01)

26.2 (± 0.1)
32.4 (± 0.1)
77.6 (±0.1)
77.6 (±0.1)
31.1 (± 0.1)
21.7 (± 0.1)
19.6 (± 0.1)
16.8 (± 0.1)
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Table 4-4.

Percentage of BAK molecules bound to BID BH3 peptides.

BID BH3 Peptides
WT
M(3)M(5)
M(3)W(5)
W(3)W(5)
M(3)Y(4)W(5)
M(3)W(4)W(5)
W(3)Y(4)W(5)
W(3)W(4)W(5)

Percent bound (%)
Peptide concentration
10 μM
30.6
69.8
93.5
97.6
86.2
92.6
76.3
84.7

1 μM
4.2
18.8
59.2
80
38.5
55.6
24.4
35.7
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50 μM
68.8
92
98.6
99.5
96.9
98.4
94.2
95.5

Novel Strategies to Crystallize BID BH3 Peptides in Complex with BAK
To mechanistically understand how BAK is activated by M(3)W(5) BID BH3 and
inhibited by W(3)W(5) BID BH3, we pursued their crystallization in complex with BAK.
Crystallization of WT BH3 peptides in complex with BAK is challenging due to their low
affinity for BAK and poor solubility. We selected the most potent BID BH3 peptide
binders to overcome these hurdles. Our previous biochemical analyses revealed that
replacement of smaller hydrophobic residues at position (3) and (5) with larger
hydrophobic residues improved their binding affinity by 50-100 fold compared to WT
BID (Table 4-2). Therefore, we first attempted to crystallize M(3)M(5) BID BH3,
M(3)W(5) BID BH3 and W(3)W(5) BID BH3 peptides in complex with WT TEV
cleaved BAK protein (WT TEV BAK) by mixing them in 1:10 (protein: peptide) molar
ratio. This strategy produced needle-like crystals of <10 μm, which diffracted to 6-8 Å
resolution even after several attempts of optimization. To overcome this bottleneck, we
devised two novel strategies for improving crystals by providing extra crystal packing
contacts to capture the peptide bound BAK structures for W(3)W(5) and M(3)W(5) BID
BH3 peptides. The first strategy entailed crystallization of the W(3)W(5) BID BH3
peptide in complex with WT TEV BAK dimer induced by CuSO4-catalyzed in situ
disulfide bond-mediated dimerization at the endogenous residue C166. WT TEV BAK
dimer of concentration 10 mg/mL (0.5 mM) was then co-crystallized with 5-fold molar
excess of W(3)W(5) BID BH3 peptide (Figures 4-11A, B). TEV BAK dimerization
under these conditions was confirmed by non-reducing SDS-PAGE (Figure 4-11C).
Long cuboidal crystals of ~100 μm size grew within 2-3 days (Figure 4-11D), and
diffracted to 1.5-Ǻ resolution (Table 4-5). Disulfide bond formation between two BAK
monomers through C166 was clearly visible in the protein-peptide complex structure
(Figure 4-12A), although there is only one monomer in the asymmetric unit. Analysis of
the W(3)W(5) BID BH3-BAK complex revealed excellent density for the peptide
including the W93(3) and W101(5) side chains. The W(3)W(5) BID BH3 peptide
engaged the BAK hydrophobic groove (delimited by α2, α3, α4, α5 and α8) and also
formed a conserved salt bridge between the side chains of D95 from the peptide and
R127 and N124 from BAK (Figure 4-12B). The second strategy involved crystallization
of the M(3)W(5) BID BH3-GGC peptide covalently tethered to engineered G184C TEV
BAK (C166S) (Figure 4-13A). The GGC linker and G184C are predicted to be
juxtaposes in the complex and formed a disulfide bond with and without treatment with
CuSO4 (Figure 4-13B). The covalent complex was confirmed by SDS-PAGE with and
without reducing agent (Figure 4-13C). CuSO4 was used as an additive in the
crystallization conditions. Long rod crystals ~50 μm in size grew within 4-5 days after
setting up the crystal screen for protein-peptide complex. (Figure 4-13D). Crystals
diffracted to 1.85-Ǻ resolution (Table 4-5). Two covalent complexes coordinated by
Cu2+ were found in the asymmetric unit (Figure 4-14A). E92 of α3 helix of BAK and
H89 and R88 of BID BH3 coordinate Cu2+ and provided extra crystal contacts to capture
the peptide in complex with the protein (Figure 4-14B). Examination of the proteinpeptide interface revealed excellent electron density for the majority of side chains of the
peptide and protein molecules (Figure 4-14C). M(3)W(5) BID BH3 peptide also engaged
the BAK hydrophobic groove peptide although the M(3) side chain did not open the
groove as wide as did the W(3) side chain.

54

Figure 4-11. Crystallization of the W(3)W(5) BID BH3-BAK complex.
A) Alignment of the amino acid sequences of the WT and W(3)W(5) BID BH3 peptides.
B) Sequential steps to crystallize the W(3)W(5) BID BH3-BAK complex.
C) Confirmation of TEV BAK dimer formation by SDS-PAGE.
D) Cuboidal crystals ~100 μm in size grew in 0.2 M potassium tartrate and 20% (w/v)
PEG 3350 and diffracted to 1.5 Ǻ.
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Table 4-5.
X-ray data collection and refinement statistics for BID BH3 peptide
bound BAK structures.

PDB ID
Data collection
Space group
Cell dimensions
a, b, c (Å)
α, β, γ (°)
Resolution (Å)
Total reflections
Unique reflections
Rmerge (%)
I / σI
Completeness (%)
Redundancy
CC1/2 (%)
Refinement
Reflections used in
refinement
Rwork / Rfree (%)
Number of atoms
Protein
Ligand/ion
Water
Average B-factor (Å2)
Protein
Ligand/ion
Water
R.M.S deviations
Bond lengths (Å)
Bond angles (°)
Ramachandran Plot
Favored (%)
Outliers (%)

W(3)W(5)-BAK
Complex
6UK7

M(3)W(5)-BAK
Complex
6UK8

I222

P212121

65.86, 70.85,
71.39
90, 90, 90
35.7 - 1.5
(1.55 - 1.50)a
185563
26921 (2574)
4.8 (45.3)
41.8 (2.4)
99.3 (97.8)
6.9 (5.2)
99.5 (88.8)

50.19, 83.18, 110.03

26907 (2578)

35670 (2082)

18.5/21.9

17.2/20.3

1445

33.02

2900
1
304
24.52
23.51
17.35
34.15

0.009
0.98

0.019
1.33

100
0

100
0

141
22.12
21.05
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90, 90, 90
37.08 - 1.85
(1.88 - 1.85)
222410
39200 (1698)
3.7 (86.3)
39.4 (1.1)
96.5 (85.2)
5.7 (4.2)
100 (67.5)

Figure 4-12. Crystal structure of W(3)W(5) BID BH3-BAK complex.
A) Crystal structure of the W(3)W(5) BID BH3-BAK complex (PDB: 4UK7). BAK
dimerization by formation of a disulfide bond involving C166 was observed in the
crystal.
B) Front view of the complex showing key stabilizing interactions through the W
substitutions and conserved salt bridge interactions (D95 vs R127 and N124) conserved
in the BCL-2 family protein complexes with BH3 ligands.
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Figure 4-13. Crystallization of the M(3)W(5) BID BH3-BAK complex.
A) Alignment of the amino acid sequences of the WT and M(3)W(5) BID BH3 peptides.
The GGC linker was introduced to facilitate disulfide bond formation to the engineered
G184C in BAK.
B) Workflow for the production of M(3)W(5) BID BH3-BAK for crystallography.
C) The complex was tested by SDS-PAGE ± reducing agent. In absence of reducing
agent, DTT, protein-peptide complex was formed readily.
D) Rod-like crystals ~50 μm in size grew in 15% PEG 4000, 0.2 M NaCl, 0.1 M MES pH
6.5 and diffracted to 1.85 Ǻ.
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Figure 4-14. Crystal structure of the M(3)W(5) BID BH3-BAK complex.
A) Cartoon representation of the two M(3)W(5) BID BH3-BAK complexes in the
asymmetric unit (PDB: 4UK8) (gray and pink). The disulfide bond between the GGC
linker of peptide and engineered G184C in BAK was clearly visible in one of the
complexes. Cu2+ forms a crystal contact stabilizing the asymmetric unit dimer.
B) Zoomed view of the coordination of Cu2+ by E92 of BAK α3 helix, and R88 and H89
of M(3)W(5) BID BH3.
C) Front view of the complex showing key stabilizing interactions through the M and W
substitutions and conserved salt bridge intercation between D95 of peptide and N124 and
R127 of BAK.
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Structural Basis of α1 Helix Displacement in Transient Direct BAK Activation
The structural mechanism of direct BAK activation by BH3-only activators is
incompletely defined. While several structures of BAK bound to BH3 ligands have
revealed similar molecular recognition of BH3 ligand at the hydrophobic activation
groove of BAK, none has directly captured the mechanism of α1 helix destabilization
associated with its activation. It has previously been identified biochemically, that upon
binding to BID BH3 activator peptide, BAK undergoes sequential conformational
changes that involves unfolding and displacement of α1 helix from protein core [22, 81,
94, 95]. Here, our structural comparisons of apo dormant BAK and BAK bound to the
M(3)W(5) BID BH3 and W(3)W(5) BID BH3 have captured for the first time
destabilization and stabilization of α1 helix required for activation or inhibition of BAK.
We analyzed the conformational changes induced at the base of the hydrophobic groove
where we specifically examined the interaction of α1 helix with α2, α3 and α5 in apo
BAK, M(3)W(5) BID BH3-BAK and W(3)W(5) BID BH3-BAK structures. The
conformational changes for all these structures are described below.
In the Apo BAK conformation, R42 and E46 on α1 helix participate in hydrogen
bonding with D90 on α3 helix and R137 on α5 helix, respectively (Figure 4-15A).
Dormant Apo BAK maintains the α1 helix in a closed conformation by blocking its
displacement from the protein core due to the formation of four, tightly coordinated Hbonds. In the activated M(3)W(5) BID BH3-BAK complex, these four bond network is
destabilized and rearranged through two hydrogen bonds between R42 on α1 helix and
N86 on α3 helix (Figure 4-15B). In the inactivated W(3)W(5) BID BH3-BAK complex,
R42 participate in hydrogen bonding with N86 and D90 while E46 participate in
hydrogen bonding with R137 (Figure 4-15C). The W(3)W(5) BID BH3-BAK complex
maintains the α1 helix in an inactivated conformation by blocking its displacement from
the rest of the protein core due to the formation of four stable hydrogen bond network.
In addition, we also examined the changes induced by M(3)W(5) BID BH3 and
W(3)W(5) BID BH3 peptides at the BAK hydrophobic groove (Figure 4-16A). The
W(3)W(5) BID BH3 peptide induced major opening of the hydrophobic groove as the
engineered Tryptophan at the 3rd position [W(3)] of the peptide accommodates the
groove. We then analyzed overlaid cartoon structures of Apo BAK with the M(3)W(5)
BID BH3 and W(3)W(5) BID BH3 bound BAK structures (Figure 4-16B). Analysis of
the aligned structures revealed outward movement of the α2, α3, α4 and α5 helices in the
peptide bound conformations. The most extensive changes were observed at the junction
of α2 and α3 as I85 and R88 on the α2 helix and Y89 and F93 on the α3 helix shifted in
an outward direction in the peptide bound structures. The W(3)W(5) BID BH3 peptide
pushed R88 and Y89 to an almost 90̊ outward position as the bulky hydrophobic
tryptophan side chain [W(3)] is accommodated in the groove.
In summary, conformational changes in BAK within and at the base of the
hydrophobic groove (i.e. α1 helix displacement) forms the basis for direct BAK
activation or inhibition. Here, we delineated for first time how of α1 helix electrostatic
may destabilized and rearranged during activation or inhibition.
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Figure 4-15. BH3 ligand induced structural conformational changes at the base of
the hydrophobic groove.
A) Electrostatic interactions stabilizing α1 helix at the base of the hydrophobic groove in
apo BAK involve formation of four hydrogen bonds.
B) The electrostatic network is destabilized with respect to apo BAK, involving two
hydrogen bonds to α1 helix, in the activating M(3)W(5) BID BH3-BAK complex.
C) The electrostatic network is re-stabilized similar to apo BAK, involving four hydrogen
bonds to α1 helix, in inactivating W(3)W(5) BID BH3-BAK complex.
Note: H-bonds interactions of ≤3.6 Å between α1 helix and other helices are colored
black.
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Figure 4-16. BH3 ligand induced changes at the hydrophobic groove of BAK.
A) Cartoon and surface representation of the peptide bound BAK complexes.
Intermolecular peptide: protein Van der Waals contacts (≤4 Ǻ) are colored light pink on
the surface. The W(3)W(5) BID BH3 peptide induced extensive opening of the
hydrophobic groove as W(3) engaged the hydrophobic groove.
B) Cartoon representation of the peptide complexes overlaid onto apo BAK. The outward
movement of the I85, R88, Y89 and F93 side chains is indicated by arrows.
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Biochemical Analysis of BAK BH3 Peptides Revealed BAK In Trans Autoactivation
Biochemical evidence suggests that active BAK exposes its BH3 region (helix α2)
which may engage the activation hydrophobic groove of nearby BAK monomers [21,
98]. Although others have proposed that active BAK can form symmetric homodimers to
mediate mitochondrial poration [92, 101], the idea of active BAK activating dormant
BAK has not been formally explored. We hypothesized that the exposed BH3 of active
BAK may autoactivate nearby dormant BAK molecules in trans through BH3-in-groove
asymmetric homodimerization. This could amplify BAK activation and enhance
mitochondrial poration. To test this hypothesis, we investigated autoactivation through
mutagenesis of BAK BH3 peptides as well as full-length proteins.
The BAK BH3 sequence is homologous to that of BID BH3 peptide (Figure
4-17A). Based on this, we designed five BAK BH3 peptides: WT BAK6t corresponds to
BAK BH3 domain sequence from S68 to Y89; WT BAK7t has four additional amino
acid residues at the C terminus; WT BAK GGC has a linker sequence to facilitate
tethering to G184C BAK; R(3) BAK BH3 and R(4) BAK BH3 include R substitutions at
the (3) and (4) positions of BAK BH3 peptide, respectively. We tested the activity of
BAK (50 nM) in response to the BAK BH3 peptides in the liposome permeabilization
assay. The WT BAK6t, WT BAK7t, and WT BAK GGC peptides at 1 and 50 µM
activate BAK, and at 50 µM WT BAK6t and WT BAK7t were better activators than WT
BID (Figure 4-17B). The R(3) BAK BH3 and R(4) BAK BH3 peptides were
significantly impaired in BAK activation compared to the WT BAK6t peptide. To
explore the structural basis for the activities of the BAK BH3 peptides, we characterized
their binding to BAK by 2D NMR analysis (Figure 4-17C). The WT BAK6t and BAK7t
peptides bind weakly to BAK revealed by resonance broadening due to intermediate
exchange (broad peaks, too weak to be detected). WT BAk7t peptide (more broad peaks)
binds slightly better than WT BAK6t, suggesting that the extra C-terminal sequence
impairs binding. The R(3) BAK BH3 and R(4) BAK BH3 peptides are completely
impaired in binding to BAK, consistent with the functional analysis. To gain further
insight into the basis for the activities of these peptides, we performed SPR assays. We
detected binding for the WT BAK6t peptide but not for the other BAK BH3 peptides.
The binding affinity of the WT BAK6t peptide (KD = 67 ± 1 µM) was similar to that of
the WT BID BH3 peptide (KD = 62.3 ± 0.4 µM) (Figure 4-17D).
In summary, the results above suggest that an exposed BAK BH3 domain, due to
displacement of the α1 and α2 helices from the globular core, may be able to activate
dormant BAK similar to BID BH3 through a transient BH3-in-groove mechanism. To
test this hypothesis further determine the structure of the complex between BAK and WT
BAK BH3 peptide.
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Figure 4-17. Biochemical analysis of BAK activation by BAK BH3 peptides.
A) Sequence alignment of BH3 peptides. Conserved residues are highlighted in black.
The GGC linker facilitates tethering to G184C BAK.
B) AUC quantification of liposome permeabilization by BAK in response to BID and
BAK BH3 peptides. Data are represented as mean + SD of three independent experiments
performed in triplicate.
C) 2D 15N-1H TROSY spectral overlay for 15N-BAK (50 μM) titrated with BAK BH3
peptides. Molar ratio of protein: peptide is color coded. BAK WT6t and BAK WT7t
peptides bind BAK weakly indicated by chemical shift perturbations in intermediate
exchange NMR regime (broadened disappearing resonances). In contrast, the R(3) BAK
BH3 and R(4) BAK BH3 peptides are completely impaired in binding.
D) Surface plasmon resonance sensorgrams for BAK titrated with the BAK BH36t
peptide revealed weak binding. MEAS-BAK-H6 was immobilized to a nickelnitrilotriacetic acid (Ni-NTA) sensor chip. The other BAK peptides did not show
evidence of binding to BAK in this assay.
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Structural Basis of In Trans Autoactivation of BAK
Due to the low affinity of BAK BH3 peptides for binding to BAK, it is
challenging to crystallize them in complex with BAK without additional engineering. We
adopted disulfide tethering similar to that used in the M(3)W(5) BID BH3-BAK complex
to stabilize a covalent complex between the WT BAK6t GGC peptide and G184C TEV
BAK (termed the BAK BH3-BAK complex) (Figure 4-18A). Crystallization of the BAK
BH3-BAK complex using CuSO4 as an additive produced microcrystals <10 µm in size
within 25-30 days (Figure 4-18B). The best out of 6 crystals diffracted to ~3.1-Å
resolution (Table 4-6). Ten complexes were found in an asymmetric unit coordinated by
Cu2+ (Figure 4-18C). All complexes have well-defined electron density for the BAK
BH36t peptide, although the C-terminal Y89 residue is not visible in three of the
complexes whereas the GGC linker is invisible in all. Analysis of one of the complexes
shows the six helical turns of the BAK BH3 peptide engaging the hydrophobic groove of
BAK, as observed in complexes of BAK with other BH3 peptides (Figures 4-18D, E).
As seen in other complexes with BH3 ligands, the BAK BH3 helix is stabilized by a salt
bridge between D83 of the peptide and R127 and N124 of BAK.
Comparison of the structures of apo BAK and BAK BH3-BAK complex revealed
BAK BH3-mediated outward movement of the α2, α3, α4 and α5 helices in the peptide
bound BAK conformation similar to the BID BH3 bound BAK structures. Overlay of apo
BAK and BAK BH3 bound complex structures revealed conformational changes at the
junction of helices α2 and α3 involving I85, R88, Y89, and F93 (Figure 4-19A). The
BAK BH3 I81(3) side chain acts as a wedge to push Y89, establishing the typical cavity
within the groove.
The BAK BH3 mediated-opening of the groove rearranged the electrostatic
network involving helix α1 at the base of the groove such that R42 and E46 of helix α1
establish two hydrogen bonds network to N86 of α3 helix, which is remarkably similar to
M(3)W(5)-BID BH3 induced rearrangement of electrostatic network of BAK (Figure
4-19B). In support of this observation, the BAK BH3-BAK complex melted at
significantly lower temperature compared to apo BAK in thermal shift assays (Figure
4-19C). Mutagenesis of α1 helix residues that stabilize dormant BAK decreases the
threshold for BAK activation in liposome permeabilization which further supports role of
α1 helix network rearrangement in BAK autoactivation (Figure 4-20).
Overall, structural-based analysis strengthened our hypothesis that the BAK BH3
domain/α2 helix is crucial for BAK in trans autoactivation, whereby BAK BH3 binds to
hydrophobic groove of an adjacent dormant BAK monomer. Alignment of Apo BAK and
the BAK BH3-BAK complex structure revealed conformational changes induced within
the hydrophobic groove similar to those observed in the activated M(3)W(5) BID BH3BAK structure. Analysis of buried electrostatic networks at the base of the groove
demonstrated altered electrostatic observations is associated with enhanced activation
similar to M(3)W(5) BID BH3-BAK structure.
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Figure 4-18. Crystal structure of the BAK BH3-BAK complex.
A) SDS-PAGE of the BAK BH3-BAK complex.
B) Microcrystals <10 µM in size grew in ~25-30 days.
C) Crystal structure of the BAK BH3-BAK complex (PDB: 4UK9) shows ten complexes
in the asymmetric unit with Cu2+ coordinating two adjacent complexes. The BAK BH3
peptide is colored blue.
D) Cartoon representation of the structure for one of the BAK BH3-BAK complex
revealed the six helical turns of the BH3 peptide bound to the hydrophobic groove of
BAK, including electrostatic interactions between D83 of the peptide and R127 and N124
of BAK.
E) Cartoon and surface representation of the structure of BAK BH3-BAK complex. Van
der Waals contacts (≤4 Ǻ) at the peptide interface are colored light pink on the surface.
BAK BH3 peptide induced extensive opening of the hydrophobic groove.
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Table 4-6.
structure.

X-ray data collection and refinement statistics for the BAK BH3-BAK

BAK BH3-BAK
Complex
6UK9

PDB ID
Data collection
Space group
Cell dimensions
a, b, c (Å)
α, β, γ (°)
Resolution (Å)

P21
89.39, 132.22, 89.38
90, 119.20, 90
29.34 – 3.06
(3.14-3.06)
86262
30995 (1458)
10.2 (54.0)
7.0 (1.3)
91.1 (58.7)
2.8 (2.1)
99.0 (60.4)

Total reflections
Unique reflections
Rmerge (%)
I / σI
Completeness (%)
Redundancy
CC1/2 (%)
Refinement
Reflections used in
refinement
Rwork / Rfree (%)
Number of atoms
Protein
Ligand/ion
Water
Average B-factor (Å2)
Protein
Ligand/ion
Water
R.M.S deviations
Bond lengths (Å)
Bond angles (°)
Ramachandran Plot
Favored (%)
Outliers (%)

28923 (1403)
21.9/25.3
13509
49
62.96
62.93
71.73
0.015
1.82
99
1
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Figure 4-19. BAK autoactivation in trans by BAK BH3 peptide induces helix α1
destabilization.
A) Cartoon representation of alignment of apo BAK (light orange) and the BAK BH3BAK structures indicates major conformational changes at the hydrophobic groove.
B) Electrostatic interactions between the α1 and α3 helices at the bottom of groove in the
BAK BH3-BAK complex forms only two hydrogen bonds.
C) Results of the thermal shift assay with 15 µM apo BAK, M(3)W(5) BID GGC-BAK
and BAK BH3-BAK complex. The complex melts at a lower temperature than apo BAK
supporting the hypothesis regarding destabilization of the BAK conformation due to
changes in the α1 helix electrostatic network.
Note: H-bonds interactions ≤3.6 Å between α1 helix and the rest of the domain are
colored black.
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Figure 4-20. Mutagenesis of helix α1 residues lowers the threshold for BAK
autoactivation.
BAK autoactivation of alanine mutants of α1 helix is measured in liposome
permeabilization assay. AUC are represented as mean + SD of three independent
experiments performed in triplicates
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Probing BAK Autoactivation Through Mutagenesis of BAK BH3 Domain
To further test the mechanism of in trans BAK autoactivation, we tested the BAK
BH3 and hydrophobic groove mutants (MEAS-BAK-H6) for autoactivation in liposome
permeabilization assay. All mutants were >95% pure, as confirmed using SDS_PAGE
(Figure 4-21A). With WT BAK, we observed BAK autoactivation only at 400 and 200
nM. At lower concentrations, BAK was activated only in the presence of 10 µM WT BID
BH3, suggesting that direct activation lowers the threshold for BAK-mediated
mitochondrial poration (Figure 4-21B). Remarkably, at 200 nM protein concentration,
several of the BAK mutants, including L78A(2), I81(3), I81R(3), I85R(4), Y89A(5),
F93A(6), D83A, and R127A, showed significantly impaired autoactivation (Figure
4-21C). In contrast, other mutants, including M71A(0), V74A(1), I85A(4), Q94(A) and
R137A, displayed autoactivation, suggesting that these residues do not play a significant
role in BAK autoactivation. Surprisingly, all of the autoactivation impaired BAK mutants
were partially active in the presence of 10 µM WT BID BH3. At a much higher protein
concentration of 800 nM, the autoactivation activity of these mutants was still severely
impaired but they could still be directly activated in the presence of WT BID BH3
(Figure 4-21D).
To probe the conformational changes of BAK in liposomes, we tested the ability
of selective mutants to be crosslinked by Glutaraldehyde (GA), which is a chemical agent
that promotes amine crosslinking (e.g., of the N-terminal amine and amine groups of
lysine residues). BAK contains one lysine (K113) and the N-terminal free amine which is
expected to extensively crosslinkWT and V74A BAK crosslink extensively, whereas
L78A and I81R crosslink poorly with and without WT BID BH3 (Figure 4-22A). We
also measured the melting temperature using the thermal shift assay. All mutants, except
D83A and I81A, melted at same or higher melting temperature compared to WT BAK
(Figure 4-22B), suggesting that mutation of these residues may possibly stabilize the fold
and may prevent destabilization upon direct activation. D83A and I81A, on the other
hand, melted at a much lower temperature than WT BAK and thus we do not believe that
reduced melting temperature directly correlates with the ability to undergo autoactivation
given that these mutants are severely impaired in autoactivation. 2D NMR (Figure
4-22C) and ITC (Figure 4-22D) binding analysis of the I81R mutant with the M(3)W(5)
BID BH3 and W(3)W(5) BID BH3 peptides revealed ~20-fold decreases in affinity
compared to binding to WT BAK, which explained the incomplete activation of this
mutant with WT BID BH3. We could not obtain quantitative parameters for binding of
the WT BID BH3 peptide to I81R BAK due to low affinity. Mutation of hydrophobic
groove residues impacts the activation and binding to BID BH3 peptides but surprisingly
not mitochondrial poration. To prove this, we tested the activity of 200 nM WT and I81R
BAK in response to the BID BH3 peptides at concentrations between 1× and 10× the KD
values for binding (Figure 4-22E). Concentrations of 4× and 10× the KD value of the
M(3)W(5) BID BH3 peptide achieved similar level of activation for the I81R mutant and
WT BAK. Concentrations of 4× and 10× the KD value of the W(3)W(5) BID BH3 peptide
achieved partial activation of the I81R BAK mutant but not to the same extent as with
WT BAK.
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Figure 4-21. BAK autoactivation is impaired in BAK BH3 and hydrophobic groove
mutants.
A) SDS-PAGE gel analysis of WT and mutant BAK (1 µM) shows that they are all of
high purity.
B) Kinetic traces and AUC quantification for BAK-mediated liposome permeabilization
in autoactivation and direct activation modes. Isolated BAK autoactivates at
concentrations of 400 and 200 nM, whereas BAK can be directly activated (by the BID
BH3 peptide) at the concentration of 50 nM.
C) AUC quantification for 200 nM WT and mutant BAK-mediated liposome
permeabilization in autoactivation and direct activation modes.
D) BAK mutants impaired in autoactivation at the concentration of 200 nM were also
impaired at 800 nM. With the exception of R127A BAK, all other BAK mutants were
partially activated by the WT BID BH3 peptide at 10 µM.
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Figure 4-22. Biochemical validation of in trans BAK autoactivation.
A) Glutaraldehyde (GA) crosslinking of BAK in the presence of liposomes. BAK was
incubated with liposomes ± WT BID BH3 at 37 °C for 90 min followed by addition of
GA for 2 hrs at RT. Immunoblotting was done using the Ab1 antibody which recognizes
a N-terminal epitope in BAK.
B) Dye-based TSA of 0.25 mg/ml BAK is represented as average + SD of Tm for three
independent experiments each performed in quadruplicate.
C) 2D 15N-1H TROSY spectral overlay of I81R BAK titrated with BID BH3 peptides.
The molar ratio of protein: peptide is color coded.
D) ITC analysis of the BID BH3 peptides binding to I81R BAK.
E) Activation of 200 nM WT and I81R BAK in response to 1×, 4× and 10× KD
concentrations of BID BH3 peptides. Although impaired in autoactivation and direct
activation, the I81R mutant of BAK is potently activated by high levels of engineered
BID BH3 peptides, indicating that mitochondrial outer membrane poration has not been
compromised.
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Our mutagenesis data support a critical role of BAK BH3 domain and the
hydrophobic groove in BAK autoactivation in trans. Additionally, our data questions the
dogmatic correlation of the ability of BAK molecules to be chemically crosslinked and to
oligomerize with mitochondrial outer membrane poration by BAK.
Direct BAK Activation with Fragment-like Small Molecules
Fragments are small molecules of molecular weight <200 Da that represent
diverse chemical space [129-131]. The C8 compound {(7-chloro-4methylbenzo[d]thiazol-2-amine)}was previously identified through ligand-based NMR
screening of the “In House” St. Jude fragment set. The results of previous 2D NMR
assays showed that this compound binds weakly to the hydrophobic groove of BAK.
Binding of C8 compound was orthogonally validated in TR-FRET assay (not shown
here). In liposome permeabilization assays, the C8 compound alone was inactive (data
not shown here). We showed that at 200 µM, the C8 compound activates WT BAK and
the WT-like V74A mutant, which is not impaired in autoactivation (Figure 4-23A). The
C8 compound (200 µM) also activates the autoactivation impaired I81R mutant of BAK,
albeit to a smaller extent than WT BID BH3 (10 µM). Remarkably, C8 activated the
R127A mutant of BAK, which is highly impaired in autoactivation, to a greater extent
than WT BAK (Figure 4-23A). We also validated activation of mouse BAK by C8
compound in MOMP assays (Figure 4-23B). In these assays, the C8 compound induced
the release of cyt c from WT but not bak-/- mitochondria in a dose-dependent manner.
We screened the remaining ~3315 fragments from the St. Jude fragment library
using ligand-based 1D NMR. The screen was performed with mixtures of 4-5 fragments
using relaxation-based and WaterLOGSY experiments. The screening results for the hitcontaining mixtures were compared with the 1D NMR spectra of individual fragments to
identify the fragments that bound to BAK (Figure 4-24). In relaxation-based SpinLOCK
experiments, the NMR signals of a fragment compound are attenuated when it binds to
BAK, while in WaterLOGSY experiments, a phase change, from negative to positive, of
the NMR signals in the presence of protein and fragments relative to fragments alone
indicates potential binding. In this screen, we discovered ~264 fragments that bound to
BAK, which corresponds to a 7.9% hit rate (Table 4-7).
In summary, the C8 compound has been identified as potential activator of BAK.
Surprisingly, in addition to WT BAK, C8 was able to activate R127A BAK, which is
completely impaired in BID-induced direct activation. This observation suggests that C8
may activate BAK through an alternative mechanism involving interactions at multiple
sites, including the hydrophobic groove and/or other allosteric interaction sites. We hope
that the studies discussed here will motivate the synthesis of analogs of the C8 compound
in the future to identify potential lead molecules with improved potency and specificity.
The additional 264 fragment hits identified here will be tested in functional and other
binding assays to discover potential lead molecules that can be merged, linked or grown
to identify potential BAK modulators.
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Figure 4-23. Activation of BAK with C8 fragment.
A) AUC quantification of liposome permeabilization by WT, V74A, I81R and R127A
BAK in the presence of WT BID BH3 and C8 is represented as mean + SD of three
independent experiments performed in triplicate.
B) C8 activation of BAK in MOMP assays induced release of cyt c from WT but not bak/mitochondria after 1 hour at 37 °C.
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Figure 4-24. 1D ligand-based NMR of a fragment mixture.
Relaxation-based and WaterLOGSY experiments are performed along with recording the
1D 1H NMR spectrum for a mixture of 4 fragments with and without BAK. Signal
attenuation and a change in sign of peaks are the signatures of binding in relaxation and
WaterLOGSY experiments, respectively (top). Hits are identified by comparing the
results of the relaxation-based and WaterLOGSY experiments with 1D 1H NMR spectra
of individual fragments (bottom).
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Table 4-7.

Summary of hits discovered through 1D ligand-based NMR screening.

Name of Fragment Library Number of
Fragments
Maybridge
Maybridge fluorinated
Three point pharmacophore
3D
Totals

1823
595
750
56
3315

Note: Hit Rate = 7.9 %
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Number of Dual Hits
Discovered through 1D Ligandbased NMR Screening
88
89
81
6
264

Modifying BCL-xL Inhibitors as BAK Modulators
The C8 compound is an analog of the BCL-xL inhibitors, A-1155463 (A5) and A1331852 (A2) [61], and indeed these compounds bind BAK. In collaboration with
medicinal chemists in the Chemical Biology and Therapeutics department, we undertook
a rational design strategy to retro-engineer the BCL-xL inhibitors into better BAK
binders with the goal of designing BAK modulators (inhibitors and activators) (Figure
4-25). Analysis using 2D 15N-1H NMR showed that the A2 and A5 BCL-xL inhibitors
bind BAK in 2D NMR, with A2 being a much better binder (Figure 4-26). The results of
2D NMR and FP binding assays revealed that deletion of the benzothiazole in A2 or A5
significantly improved binding to BAK (Table 4-8). The A2 analogs appear to bind with
higher affinity than the A5 analogs (Figure 4-27A, B). We tested the activation of BAK
in response to these compounds in cyt c release assay (Figure 4-28). A2 released cyt c at
100 µM and 50 µM doses in WT mitochondria and at 100 µM in bak-/- mitochondria. The
ADMN094 analog of A2 induce cyt c release at 100 and 50 µM in WT but not in bak-/mitochondria. Similarly, the A5 and its analog, M92, showed cyt c release at the higher
doses, 100, 50 and 25 µM with M92 showing greater activation than A5.
We crystallized the A2 analog, BMYN 75-5, in complex with BAK. We
incubated 10 mg/ml WT TEV BAK with 500 µM CuSO4 and 4-5 mM BMYN 75-5 and
observed lemon shaped crystals ~100 µm in length (Figure 4-29A) diffracted to ~1.5 Å
resolution. The crystal structure revealed that the compound binds to the P3-P5 sub
pockets of the BAK hydrophobic groove. An overlay of the BMYN 75-5-BAK complex
with apo BAK showed minor conformation changes in the hydrophobic groove (Figure
4-30). The electrostatic network involving helix α1 is similar to that found in apo BAK;
for example, R42 forms two hydrogen bonds with D90 and E46 forms two hydrogen
bonds with R137, which, together, maintain BAK in a dormant conformation. Apo BAK
dormant conformation of this complex explains no BAK activity in cyt c release assay
(Figure 4-28).
Structure-based drug design approaches will be required to convert these
molecules into potent BAK activator or inhibitor compounds. Extension of the A2 analog
towards the P2, P1 and P0 sub pockets of hydrophobic groove and exploring more
diverse chemical space might induce conformational changes to activate or inhibit BAK.
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Figure 4-25. Modified analogs of Bcl-xL inhibitors.
Analogs were synthesized from two BCL-xL inhibitors (A-1331852 and A-1155465) to
test cross reactivity with BAK.
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Figure 4-26. Two-dimensional (2D) NMR binding analysis of BCL-xL analogs to
BAK.
Overlaid 2D 15N-1H TROSY spectra for WT TEV BAK (50 μM) titrated with 7 different
compounds. The molar ratio of protein: compounds is color coded.
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Table 4-8.
Summary of NMR KD and FP IC50 for rationally designed
compounds.
Compounds
A-1331852 (A2)
ADMN094
BMYN 75-5
BMYN 83-2
BMYM 79-2
A-1155465 (A5)
M92

NMR KD (µM)
ND
171 ± 66.6
79.6 ± 14.62
15.1 ± 2.2
ND
ND
190.8 ± 17.3
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FP IC50 (µM)
ND
125.3 ± 42.38
6.5 ± 16.57
ND
ND
ND
ND

Figure 4-27. 2D NMR CSPs and Fluorescence Polarization data on the binding of
BID BH3 peptides to BAK.
A) 2D 15N-1H NMR CSPs) for 15N-BAK in the presence of selected compounds (800
μM). For resonances in the fast exchange regime (orange), CSPs are described as ≥ 1 SD
above the average between significant and insignificant CSPs; resonances in the
intermediate and slow exchange regime (red) were all assigned CSP value of 0.1 ppm;
overlapping resonances (blue) and resonances with insignificant CSPs (black) are also
plotted.
B) Fluorescence Polarization assay results for selected compounds.
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Figure 4-28. Cyt c release assay for A-1155463 (A5) and A1331852 (A2) analogs.
Results of cyt c release assays performed to assess the activity of BAK in response to
compounds. Western blot images represent the release of cyt c from mitochondria into
supernatant when incubated in the presence of the noted concentrations of the compounds
at 37 ̊C.
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Figure 4-29. Crystal structure of BMYN 75-5 bound to WT TEV BAK.
A) Lemon shaped crystals of ~100 μm in length grown in 0.6 M sodium dihydrogen
phosphate/0.6 M potassium dihydrogen phosphate, 0.075 M Sodium HEPES pH 7.5, and
25% (v/v) Glycerol diffracted up to 1.5 Ǻ resolution.
B) The compound BMYN 75-5 binds to the P3-P5 pockets of the BAK hydrophobic
groove.
C) Overlay of the compound: BAK complex (gray) and Apo BAK (light orange)
structures.
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Figure 4-30. The structure of the BMYN 75-5-BAK complex reveals a buried
electrostatic network involving α1 helix similar to that observed in the apo BAK.
The buried electrostatic interactions at the bottom of the hydrophobic remains in a
dormant conformation similar to Apo BAK.
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CHAPTER 5.

DISCUSSION

Our studies defined mechanistic details of transient direct activation and
autoactivation of BAK involved in mitochondrial apoptosis. Here, we clearly present the
biochemical and structural evidence to support direct activation and autoactivation of
BAK which is not completely understood yet mechanistically. We elucidated specific
novel molecular determinants required for direct activation and autoactivation of BAK.
The biochemical studies have proved that α1 helix is displaced from the BAK protein
core upon BH3-only proteins binding to hydrophobic groove [22, 23, 81, 94]. We
discovered specific molecular changes following BH3-only initiators engagement of
hydrophobic groove of BAK. These changes induce α1 helix destabilization in direct
activation and autoactivation.
Based on NMR solution structure of BID SAHB-BAK complex, α1 helix lies
underneath the interaction site of C-terminal of BID BH3 and BAK hydrophobic groove
[22], we postulated that C-terminal residues of BID might be crucial for α1 helix
conformational transition. Indeed, chimeric BH3-only peptides (BMF BID, BIM BID,
NOXA BID, and PUMA BID) designed by swapping six C-terminal BID residues
induced significantly higher level of BAK activation as compared to their parent peptides
in both liposome permeabilization and cyt c release assays. BMF is a derepressor BH3only protein which does not activate BAK directly; therefore, direct significant BAK
activation was observed in response to BMF BID chimera peptide. Overall this analysis
provided insights that α1 helix is crucial for BAK activation.
Hit-and-run activation mechanism (transient activation mechanism) of BAK has
been proposed based on the biochemical observation that BID BH3 activator peptide
engages hydrophobic groove with weak affinity (KD~10 μM) [22, 93, 128]. According to
this model, BID activator must dissociate from groove of BAK to allow further
downstream conformation modifications necessary for unfolding and activation of BAK.
Our current in vitro and structural results of di- and tri substituted BID BH3 peptides in
complex with BAK further strengthened this hypothesis and uncovered novel molecular
modifications induced at the base of the groove. SPR association and dissociation rates
suggested that weaker affinity of BID BH3 with BAK is not the only factor to determine
the hit-and-run activation mechanism since some of the high affinity peptides also
induced BAK activation. Instead how fast these peptides dissociate from the groove
determines transient activation mechanism. At lower 1 μM peptide concentration, it was
interesting to observe that all peptides were able to induce BAK activation in liposome
permeabilization assay probably due to low occupancy of peptides at the hydrophobic
groove. Furthermore, comparisons of α1 helix electrostatic interactions with the rest of
the protein core in apo BAK, partially activated M(3)W(5)-BAK and inhibited
W(3)W(5)-BAK crystal structures suggested that these molecular changes also
contributes in BAK activation. We can possibly explain why some of the high affinity
peptide binders are partial activators [e.g. M(3)W(5) BID BH3] as they destabilize
underlying electrostatic interactions of α1 helix with rest of the protein core and do not
rearrange them in inhibitory conformation [e.g. W(3)W(5) BID BH3]. In other study,
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BIM BH3 activator peptide converted into an inhibitor peptides by introducing a bulky
carboxylic acid containing, non-natural amino acid at the hydrophobic position 3 of the
BIM peptide [80]. The KD values of these peptides were in low nanomolar range and they
completely blocked BAK activity in liposome permeabilization and cyt c release assays.
The crystal structures of these peptides in complex with BAK revealed “glue-like”
charge-charge interactions between non-natural amino acid and residues on α1 helix,
which blocked its dissociation from its protein core. We can possibly conclude that
combined factors such as affinity of BID BH3 peptides, their association and dissociation
rates and how their binding to groove impact α1 helix electrostatic interactions determine
BAK activation or inhibition.
Through our efforts to understand structural-based BAK activation mechanism,
we discovered novel and efficient co-crystallization strategies to capture weak affinity
BH3 peptides in complex with BAK at high resolution. Our first co-crystallization
strategy involved the addition of Copper Sulfate in crystallization trials to facilitate in situ
inter-molecular disulfide bond formation through C166 of WT TEV BAK. Dimer
formation of BAK through C166 apparently stabilized BAK’s interactions with peptides
and produced the crystal structure of W(3)W(5) BID BH3 in complex with WT TEV
BAK. In another strategy, we introduced a GGC linker at the C-terminal of BID peptides
and a cysteine on the C-terminal of the TEV BAK protein. Disulfide bond tethering of a
peptide to the protein produced the crystal structure of M(3)W(5) BID BH3 GGC BIDG184C TEV BAK. Both strategies resulted in high resolution structures that informed us
on the BAK conformational changes induced both at the hydrophobic groove and at the
base of hydrophobic groove. In situ inter-molecular disulfide bond formation has been
proven successful to co-crystallize potential BAK modulators in complex with BAK,
which is guiding BAK drug discovery in cancer research. In previous studies,
hydrocarbon stapling by introducing non-natural amino acids in the peptides has been
proven partially successful to capture protein-peptide complexes [132]. Hydrocarbon
stapling of the WT BID BH3 peptide enabled determination of the solution structure of
BID SAHB bound to BAK using NMR spectroscopy and described the molecular
mechanism of BAK direct activation. Other strategies used detergent induced domain
swapped BAK dimer, where helices α2 - α5 were separated from helices α6 - α8 [80, 92,
99]. This dimer revealed a stable interface which promotes crystallization of BH3
peptides in complex with BAK probably due to exposure of some residues (L100 of
BAK) crucial for forming the protein-peptide complex. However, both strategies revealed
drawbacks since it was difficult to clearly identify α1 helix electrostatic interactions at the
base of the groove.
The W(3)W(5) BID BH3 peptide, the most potent binder (KD ~260 nM), induced
dramatic conformational changes within the BAK hydrophobic groove by pushing α2, α3
and α4 in the outwards direction as compared to the dormant Apo BAK conformation.
The most dramatic changes were observed for side chains I85, R88, Y89 and F93 as they
flipped out almost by 90 ̊ in the outwards direction as the peptide accommodated the
groove. The M(3)W(5) BID BH3 peptide activated BAK partially in liposome
permeabilization assay while the W(3)W(5) BID BH3 peptide completely inhibited its
activity. Dissociation of the α1 helix is an early step in the BAK conformation transitions
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associated with activation [81, 94, 95]. By examining the interaction of α1 helix with α2,
α3 and α5 in the apo BAK, M(3)W(5) BID BH3-BAK and W(3)W(5) BID BH3-BAK
structures, we identified structural features associated with the dormant, activated and
inhibited conformations of BAK. In apo BAK, the α1 helix is stabilized by networks of
electrostatic interactions with the α2, α3 and α5 helices. In contrast, in the M(3)W(5) BID
BH3-BAK activated complex, the electrostatic network involving the α1 helix is
rearranged to include only two electrostatic interactions with the α2 helix. In the inhibited
W(3)W(5) BID BH3-BAK complex, these interactions were rearranged to include four
electrostatic interactions with the α2, α3 and α5 helices. These observations are consistent
with our hypothesis that rearrangements of electrostatic interactions at the base of the
hydrophobic groove of the BAK on the one hand facilitate α1 helix dissociation in the
case of activation but on the other are also associated with inhibition. Specific residues
involved in stabilizing the α1 helix are R42 and E46. The substitution of these residues
with alanine significantly decreased the threshold for BAK auto activation at 100 nM and
200 nM protein concentration in liposome permeabilization assays. Furthermore, other
studies have shown that disulfide bond tethering of α1 helix with α2 or other helices
blocks BAK activation [95]. Also, the BIM H3Pc peptide blocked BAK activation by
forming a stable electrostatic interaction between the carboxylate group of a non-natural
amino in the peptide and R42 on the α1 helix of BAK [80]. Through our systematic
comparison of different conformations of dormant apo BAK, the activated M(3)W(5)
BID BH3-BAK complex and the inhibited W(3)W(5) BID BH3-BAK complex, we
provide well supported suggestions regarding the structural basis of α1 helix dissociation
as a requirement for BAK direct activation.
Upon direct BAK activation, the BH3 domain of BAK is exposed and proposed
by others to form “BH3-in-groove” symmetric dimers [92, 98, 101, 133]. Although
truncated BAK constructs (containing the α2 - α5 helices) provided preliminary evidence
for formation of BAK dimers, how these dimers mediate BAK activation and whether
they form in the context of full length BAK is unclear. Our studies further elaborated the
crucial role of the BH3 domain activation of dormant BAK through a mechanism we
termed BAK autoactivation. Based on sequence homology of the BID BH3 and BAK
BH3 peptides, we predicted that the BAK BH3 might also have a crucial role in BAK
activation similar to that of the WT BID BH3. We observed that different versions of
BAK BH3 peptides (WT BAK6t, WT BAK7t, and WT BAK GGC) were able to activate
BAK in liposome permeabilization assays, which is consistent with our autoactivation
hypothesis. Interestingly, we discovered that at 50 µM peptide concentration, WT BAK6t
BH3 peptide induced significantly greater activation than WT BID BH3. It is possible
that BAK autoactivation also utilizes the transient hit-and-run mechanism similar to BID
BH3 induced direct BAK activation. Indeed, the lower binding affinity of the WT BAK6t
BH3 peptide in SPR and 2D NMR assays reflects transient interaction with BAK.
Surprisingly, the KD value for the BAK BH3 peptide determined using SPR is slightly
higher (lower affinity) than that for the BID BH3 peptide, indicating that BAK
autoactivation might rely on more transient interactions than direct BAK activation. The
structure of the WT BAK6t peptide bound to BAK shows that six hydrophobic residues
(T70, M71, V74, L78, I81, I85, Y89) are accommodated deep within the hydrophobic
groove. A conserved salt bridge interaction between D83 of the peptide and R127 of
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BAK is also observed. Replacing residues I81 and I85 within the BAK BH3 peptide to
arginine significantly impaired BAK activation in liposome permeabilization assays,
suggesting that these residues have roles in BAK autoactivation. Interaction of the α1
helix with other helices revealed only two electrostatic interactions also observed in the
activated M(3)W(5) BID BH3-BAK complex, where the α1 helix interacts only with the
α2 helix. Mutation of the BH3 domain and groove residues of full length BAK protein
(e.g., I81R and L78A) completely abolished BAK autoactivation in liposome
permeabilization assays, which further strengthened our hypothesis regarding the BAK
autoactivation mechanism. Surprisingly, these BAK mutants were partially directly
activated by the WT BID BH3 peptide, indicating that both activation mechanisms might
be required simultaneously to amplify BAK activation and mitochondrial poration.
Earlier studies also provided preliminary biochemical evidence of BAK and BAX
autoactivation as chimeric BIM and BID peptides, containing the BAK and BAX BH3
domains, activated BAK and BAX in cyt c release assays [21]. Another study revealed
that a N-terminally truncated BAK mutant induced oligomerization of endogenous BAK
in a mitochondrial assay [134]. Finally, results from studies of a HCT116 cell line in
which all of the BH3-only proteins were knocked out suggested that direct activation by
these proteins is not necessary and that other BAK activation mechanism(s) are operative
(e.g., autoactivation) [135, 136]. We also utilized HCT116 cell lines to validate
autoactivation and direct activation mechanism in cells (results not shown in this
dissertation). HCT116 cell lines lacking genetic expression of 17 BCL-2 family members
were stably reconstituted with full length human BAK with mCherry tag on N-terminal to
measure BAK autoactivation based on doxycycline (Dox)-inducible Tet-On 3G retroviral
system. V74A(1), I81A(3), I81R(3) and D83A(s) BAK constructs with mCherry tag were
cloned and reconstituted in HCT116 cell lines and doxycycline-induced cell death was
measured using DNA-binding dye SYTOX Green. V74A BAK induced significant faster
cell death than I81A, I81R and D83A at all doxycycline concentrations, which is
consistent with our liposome permebailization-based biochemical analysis. Direct
activation was measured by reconstituting full length human BID construct in addition to
V74A full length human BAK construct in HCT116 cell lines. TRAIL and cycloheximide
was added to induce the expression of BID as TRAIL activates caspase-8 which
subsequently cleaves BID into activated truncated form (tBID) to drive cell death. Cell
death was enhanced in the presence of BID, V74A-BAK, doxycycline, TRAIL and
cycloheximide than V74A-BAK with doxycycline alone. Enhancement of cell death and
BAK activation in the presence indicates cooperation of autoactivation and direct
activation in these cell lines.
Future Directions in the Context of BAK Assembly on Outer Mitochondrial
Membrane
To further understand how BAK monomers are organized onto mitochondrial
membrane and autoactivated, high resolution techniques such as cryo EM are required.
Cryo EM or NMR structure of full length BAK protein in the presence of detergents,
nanodisc and liposome model system may provide complete understanding of activation
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and pore formation mechanism. However, due to size limitation with cryo EM
techniques, fusion of larger tags similar to GPCR proteins family engineering will be
required to capture the high resolution structure.
Insights and Future Directions in the Context of BAK Targeting
The equilibrium between expression level of proapoptotic and prosurvival
guardians is required to set the threshold for mitochondrial apoptosis initiation, which is
disrupted during cancer progression and other diseases such as autoimmunity. Despite
drug discovery progress towards targeting almost all prosurvival guardians and
proapoptotic members, only ABT-199 has received FDA approval for chronic
lymphocytic leukemia treatment. Successful approval of ABT-199 took decades of
efforts associated with several failures of early phase small molecules. ABT-199 is
specific for BCL-2-dependent malignancies. However, overexpressed prosurvival
guardians or mutated proapototic proteins have been found in other tumor types as well.
Therefore, rapid clinical drug development is required to treat tumors these tumors. ABT199 has also shown to acquire resistance as disease reoccurred in patients after 2-3 years
of treatment. Experimental and clinical studies proved that in some cases ABT-199 drug
resistance resulted due to single amino acid mutations within the BH3 binding pocket of
BCL-2, which reduced the binding of ABT-199 within BH3 binding pocket [137, 138].
Additionally, mutations in BAX resulting in truncation and poor mitochondrial targeting
lead to resistance to ABT-199 in the absence of BCL-2 mutations Thus, drug resistance
poses a further challenge to target BCL-2 family members and requires effective
strategies to overcome drug resistance challenges.
BAK and BAX modulators can be used in combination with inhibitors of
prosurvival guardians which may reduce the threshold for mitochondrial apoptosis.
However, progress towards designing BAK and BAX modulators is in premature phase
and only BAX activator, BTSA-1 has entered in preclinical testing stage for AML
treatment. The majority of BAK and BAX modulators discovered so far are very
hydrophobic in nature and due to lack of co-crystal structures, their direct mode of
interaction is not known. It is possible that these molecules directly interact with outer
mitochondrial membrane rather modulating BAK or BAX specifically. Nonetheless, the
crystal of modified BIM peptides in complex with BAK have laid the foundation to
understand the mechanism of action required for BAK inhibition by blocking α1 helix
dissociation.
From these past efforts it is obvious that a pressing need remains in targeting
BCL-2 family members. Therefore, it becomes crucial to understand the underlying
mechanism of regulation prior to rational drug design to target specific BCL-2 family
proteins. Towards the goal of targeting BAK we tested mutated BID peptides to explore
the activation or inhibition hotspots. It has been proposed earlier that alanine substitution
of seven smaller hydrophobic residues of BID (I81, I82, I86, L90, V93, M97 and I101)
impairs BAK activity. To further explore the individual contributions of these
hydrophobic residues (0-5 position) of BID in direct activation, larger hydrophobic
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residues (M, F, Y and W) were introduced at each of these positions. Interestingly, our
combined functional and binding analysis with sixteen mutated BID BH3 peptides
provided an overview of depth and plasticity of the hydrophobic groove sub pockets.
From this analysis, we concluded that the P1 and P2 sub pockets are shallow and the P0,
and P3-P5 sub pockets are deep and plastic to accommodate large hydrophobic residues.
Knowledge of the plasticity of the hydrophobic groove is crucial from the point of view
of drug discovery efforts to target BAK. The prosurvival guardians inhibitors or BH3mimetics were designed based on the knowledge of the depth and plasticity of their
hydrophobic groove sub pockets and subsequent optimization through structure-based
drug design approaches [46, 47]. Subtle structural differences in the hydrophobic groove
sub pockets of the BCL-2 protein family members laid the foundation to design more
selective inhibitors; these include, ABT-199 for BCL-2 [56, 57], A-1331852 (A2) [61]
for BCL-xL and S63845 for MCL-1 [67]. We can potentially design BAK selective
modulators by incorporating large chemical entities in P0 and P3-P5 sub pockets and
small chemical entities in the P1 and P2 sub pockets. Specifically, the P3 and P5 sub
pockets seem more plastic and have the potential to fit larger and flexible chemical
entities. To test this hypothesis, we tested analogs of Bcl-xL inhibitors which may extend
to the P3-P5 sub pockets [A-1331852 (A2) and A-1155465 (A5)]. Deletion of
benzothiazole group of A2 and A5 improved the binding affinity by several folds
specifically for A-1331852 modified analogs. Due to improved binding affinity, for the
first time we were able to capture the co-crystal structure of A2 analog bound to BAK.
The crystal structure revealed that A2 analog indeed bound to P3-P5 sub pockets of
hydrophobic groove and induce minor conformational changes at hydrophobic groove
and no changes at the base of the groove, which maintains BAK in apo conformation.
From this analysis, we learned that further optimization of A2 analogs is required to
induce conformational changes at the activation groove similar to destabilization or restabilization of α1 helix by BH3 ligand-binding leading to activation or inhibition of
BAK, respectively.
BAK modulators can be designed by mimicking M(3)W(5) and W(3)W(5) BID
BH3 peptides, which induce subtle molecular changes at the hydrophobic groove and at
its base that have profoundly different functional outcomes—activation and inactivation,
respectively. They can also be designed by mimicking BIM modified peptides which may
directly interact with α1 helix in “glue-like” fashion to block its dissociation. The fact
that ABT-199 and other antiapoptotic targeting compounds were discovered through
fragment-based NMR screening approaches suggests that similar strategies can be
adopted to discover BAK modulators that can selectively target BAK hydrophobic sub
pockets and avoid off-target effects. C8 compound in our fragment-based screening has
shown promising results in in vitro and cell death assays (data not discussed in this
dissertation) and may be a good starting point to design potential lead compounds. More
analogs of C8 and A2 compounds are being synthesized at Chemical Centers in CBT at
St. Jude and will be tested in the future for their structure and function to inhibit or
activate BAK.
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